NOR-SOLIDARITY First Interim Report

Inge Christoffer Olsen, PhD

29 December, 2020

Table of Contents

[2 Introduction 2](#_Toc60138199)

[3 Inclusion status 3](#_Toc60138200)

[3.1 Inclusion rate 3](#_Toc60138201)

[3.2 Inclusion by hospital 4](#_Toc60138202)

[3.3 By treatment 5](#_Toc60138203)

[4 Patient flow 9](#_Toc60138204)

[5 Demographics 10](#_Toc60138205)

[6 Exposure 24](#_Toc60138206)

[7 Efficacy 25](#_Toc60138207)

[7.1 Mortality 25](#_Toc60138208)

[7.1.1 Descriptives 25](#_Toc60138209)

[7.1.2 Plots 26](#_Toc60138210)

[7.1.3 Efficacy estimates 35](#_Toc60138211)

[7.2 Viral load 37](#_Toc60138212)

[7.3 Dichotomous endpoints 40](#_Toc60138213)

[7.3.1 Descriptives 40](#_Toc60138214)

[7.3.2 Marginal probability estimates by treatment group and difference 41](#_Toc60138215)

[7.4 Inflammatory laboratory parameters 43](#_Toc60138216)

[7.4.1 Descriptives 43](#_Toc60138217)

[7.4.2 Plots 67](#_Toc60138218)

[7.4.3 Efficacy estimates 79](#_Toc60138219)

[7.5 SARS-CoV2 antibodies at day 90 84](#_Toc60138220)

[7.5.1 Descriptives 84](#_Toc60138221)

[7.5.2 Marginal probability estimates by treatment group and difference 85](#_Toc60138222)

[7.6 Time to last discharge 86](#_Toc60138223)

[7.6.1 HCQ 86](#_Toc60138224)

[7.6.2 Remdesivir 89](#_Toc60138225)

[8 Adverse Events 92](#_Toc60138226)

[8.1 AE Summary 92](#_Toc60138227)

[8.2 By System Organ Class and Preferred Term 92](#_Toc60138228)

[8.3 Serious Adverse Events 96](#_Toc60138229)


[8.4 Suspected Unexpected Serious Adverse Reaction 99](#_Toc60138230)

# Introduction


This is the report for the first interim analysis of the NOR-SOLIDARITY trial. The data are based on an export from the Viedoc electronic data capture at “2020-11-21 15:46:31” system time stamped “ous\_20201121\_154631”. While the results are based on real data, the treatment allocation has been drawn randomly for this report. Thus, this is a mock-up report intended to show how the final report will look like, without showing the actual results of the trial and the treatment differences. There were 181 included patients.

# Inclusion status




## Inclusion rate



## Inclusion by hospital



## By treatment



# Patient flow

## Note: Using an external vector in selections is ambiguous.  
## ℹ Use `all\_of(group)` instead of `group` to silence this message.  
## ℹ See <https://tidyselect.r-lib.org/reference/faq-external-vector.html>.  
## This message is displayed once per session.

Patient flow total

|  |  |
| --- | --- |
| Parameter | Total |
| Enrolled | 186 (100%) |
| Randomised | 185 (99.5%) |
| Included in FAS | 181 (97.3%) |
| Excluded from FAS, No post-randomisation information | 4 (2.2%) |
| Excluded from FAS, incorrect inclusion | 1 (0.5%) |

Patient flow by arm

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC | SOC + HCQ | SOC + Remdesivir |
| Randomised | 88 (100%) | 54 (100%) | 43 (100%) |
| Included in FAS | 87 (98.9%) | 52 (96.3%) | 42 (97.7%) |
| Excluded from FAS, No post-randomisation information | 1 (1.1%) | 1 (1.9%) | 1 (2.3%) |
| Excluded from FAS, incorrect inclusion | 0 (0%) | 1 (1.9%) | 0 (0%) |

Patient flow during study (FAS)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Reason | Standard of care (SOC) | Hydroxychloroquine + SOC | Remdesivir + SOC | Total |
| Voluntary discontinuation by the patient | 3 | 3 | 1 | 7 |
| Patient lost to follow-up | 2 | 2 | 2 | 6 |
| Death | 5 | 5 | 2 | 12 |
| Other | 5 | 0 | 1 | 6 |
| Completed | 72 | 42 | 36 | 150 |

# Demographics

Demographics, all patients (FAS)

|  |  |
| --- | --- |
| Parameter | All patients (N=181) |
| **Demographics** |  |
| Age (years) | 59.8 (15.3) |
| Female, n (%) | 62 (34.3%) |
| Body Mass Index (kg/m2) | 28 (5) |
| Body Mass Index (kg/m2) | 27 (25 - 31) |
| Symptoms prior to admission (days) | 8 (4.9) |
| P/F-ratio at admittance (kPa) | 41 (13) |
| P/F-ratio < 40kPa, n (%) | 77 (43%) |
| Temperature (°C) | 37.4 (0.9) |
| Admitted to ward, n(%) | 171 (94.5%) |
| Admitted to ICU, n(%) | 10 (5.5%) |
| WHO Moderate disease state (4-5), n(%) | 171 (94.5%) |
| WHO Severe disease state (6-9), n(%) | 10 (5.5%) |
| WHO Severe disease state (6), n(%) | 5 (2.8%) |
| WHO Severe disease state (5), n(%) | 90 (49.7%) |
| **Comorbidities** |  |
| Chronic cardiac disease, including congenital heart disease | 28 (15.6%) |
| Chronic pulmonary disease, n(%) | 10 (5.6%) |
| Ever smoking, n(%) | 71 (39.4%) |
| Hypertension, n(%) | 55 (30.6%) |
| Diabetes, n(%) | 31 (17.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 44 (26.8%) |
| **Co-medications** |  |
| Steroids | 8 (4.5%) |
| Other immunomodulatory drugs | 8 (4.5%) |
| ACE inhibitor | 12 (6.7%) |
| AT-II blockers | 30 (16.8%) |
| **Hematology** |  |
| Hemoglobin (g/dL) | 13.2 (12.3 - 14.1) |
| WBC (x109/L) | 6.2 (4.7 - 8.7) |
| Neutrophils (x109/L) | 4.3 (3 - 6.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.4) |
| Platelet counts (x10^9/L) | 202.5 (158.5 - 270.5) |
| **Inflammatory markers** |  |
| CRP (mg/L) | 70 (36.5 - 137.5) |
| Procalcitonin (µg/L) | 0.12 (0.1 - 0.21) |
| Ferritin (µg/L) | 613 (319 - 1173) |
| **Other** |  |
| LDH (U/L) | 277 (214 - 360) |
| D-dimer (mg/L FEU) | 0.68 (0.45 - 1.12) |
| AST | 39 (27.2 - 59) |
| ALT | 33 (20 - 58) |
| eGFR (mL/min/1.73 m2) | 89.7 (74.2 - 105.5) |
| **Viral count** |  |
| Viral count (log10 counts/1000 cells) | 2 (1.6) |
| **Anti-SARS-CoV-2 Antibodies** |  |
| Zero converted (RBD ≤ 5) | 67 (52.8%) |
| **Supplementary baseline information** |  |
| Systolic Blood Pressure (mmHg) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 74 (11) |
| Mean Arterial Blood Pressure (mmHg) | 91 (12) |
| SOFA score | 1.6 (1.6) |
| Chronic kidney disease, n(%) | 11 (6.1%) |
| Autoimmune disease, n(%) | 8 (4.4%) |
| Cognitive impairment/dementia, n(%) | 4 (2.2%) |
| Neurological disorder, n(%) | 7 (3.9%) |
| Cancer, n(%) | 13 (7.2%) |
| Cirrhosis, n(%) | 0 (0%) |
| Asthma, n(%) | 22 (12.2%) |
| HIV, n(%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |

Demographics, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 59.2 (16.2) | 59.4 (13.4) | 61.4 (16.1) |
| Female, n (%) | 34 (39.1%) | 15 (28.8%) | 13 (31%) |
| Body Mass Index (kg/m2) | 28 (5) | 28 (4) | 28 (5) |
| Body Mass Index (kg/m2) | 28 (24 - 32) | 27 (25 - 30) | 27 (25 - 30) |
| Symptoms prior to admission (days) | 8.4 (6) | 7.5 (4) | 7.9 (3.2) |
| P/F-ratio at admittance (kPa) | 40 (13) | 40 (15) | 44 (10) |
| P/F-ratio < 40kPa, n (%) | 39 (45.3%) | 25 (48.1%) | 13 (31.7%) |
| Temperature (°C) | 37.4 (0.9) | 37.4 (0.9) | 37.4 (0.9) |
| Admitted to ward, n(%) | 84 (96.6%) | 47 (90.4%) | 40 (95.2%) |
| Admitted to ICU, n(%) | 3 (3.4%) | 5 (9.6%) | 2 (4.8%) |
| WHO Moderate disease state (4-5), n(%) | 84 (96.6%) | 48 (92.3%) | 39 (92.9%) |
| WHO Severe disease state (6-9), n(%) | 3 (3.4%) | 4 (7.7%) | 3 (7.1%) |
| WHO Severe disease state (6), n(%) | 1 (1.1%) | 2 (3.8%) | 2 (4.8%) |
| WHO Severe disease state (5), n(%) | 51 (58.6%) | 25 (48.1%) | 14 (33.3%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 10 (11.6%) | 9 (17.3%) | 9 (21.4%) |
| Chronic pulmonary disease, n(%) | 6 (7%) | 3 (5.8%) | 1 (2.4%) |
| Ever smoking, n(%) | 34 (39.5%) | 18 (34.6%) | 19 (45.2%) |
| Hypertension, n(%) | 27 (31.4%) | 18 (34.6%) | 10 (23.8%) |
| Diabetes, n(%) | 15 (17.4%) | 13 (25%) | 3 (7.1%) |
| Obese (BMI > 30 kg/m2), n(%) | 24 (30%) | 11 (24.4%) | 9 (23.1%) |
| **Co-medications** |  |  |  |
| Steroids | 3 (3.5%) | 3 (5.9%) | 2 (4.8%) |
| Other immunomodulatory drugs | 5 (5.8%) | 1 (2%) | 2 (4.8%) |
| ACE inhibitor | 4 (4.7%) | 6 (11.8%) | 2 (4.8%) |
| AT-II blockers | 13 (15.1%) | 9 (17.6%) | 8 (19%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 13.2 (12.2 - 14) | 13.4 (12.9 - 14.5) | 13.1 (12 - 13.9) |
| WBC (x109/L) | 6.3 (4.8 - 9.1) | 6 (4.6 - 8.2) | 5.8 (4.7 - 7.4) |
| Neutrophils (x109/L) | 4.8 (2.9 - 7) | 4.3 (3.2 - 5.6) | 4 (2.5 - 6.5) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.4) | 1 (0.8 - 1.3) | 1 (0.8 - 1.6) |
| Platelet counts (x10^9/L) | 211.5 (161.2 - 286.5) | 186 (158 - 238) | 176 (156 - 279) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 83 (50 - 152) | 61.5 (31.8 - 112) | 64.5 (29.2 - 129) |
| Procalcitonin (µg/L) | 0.14 (0.1 - 0.24) | 0.1 (0.1 - 0.2) | 0.12 (0.1 - 0.2) |
| Ferritin (µg/L) | 539 (301 - 1109) | 608 (276 - 1103.5) | 677 (442 - 1488) |
| **Other** |  |  |  |
| LDH (U/L) | 271 (209.2 - 353.5) | 275 (220.5 - 367.5) | 287 (214.8 - 361) |
| D-dimer (mg/L FEU) | 0.75 (0.5 - 1.19) | 0.6 (0.41 - 1) | 0.8 (0.44 - 1.04) |
| AST | 38 (28 - 65) | 43 (28 - 52) | 46 (27 - 63.5) |
| ALT | 31 (19 - 67) | 36.5 (22 - 52.5) | 32 (22 - 62.5) |
| eGFR (mL/min/1.73 m2) | 89.8 (73.8 - 106.2) | 85.7 (73.8 - 100.4) | 90.8 (76.9 - 105.1) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 1.9 (1.6) | 2.2 (1.6) | 2 (1.7) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| Zero converted (RBD ≤ 5) | 34 (54.8%) | 23 (62.2%) | 10 (35.7%) |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 124 (17) | 131 (17) | 121 (18) |
| Diastolic Blood Pressure (mmHg) | 72 (10) | 77 (11) | 72 (13) |
| Mean Arterial Blood Pressure (mmHg) | 89 (11) | 95 (12) | 88 (13) |
| SOFA score | 1.6 (1.5) | 1.8 (2.1) | 1.3 (1.3) |
| Chronic kidney disease, n(%) | 6 (7%) | 2 (3.8%) | 3 (7.1%) |
| Autoimmune disease, n(%) | 5 (5.8%) | 0 (0%) | 3 (7.1%) |
| Cognitive impairment/dementia, n(%) | 3 (3.5%) | 1 (1.9%) | 0 (0%) |
| Neurological disorder, n(%) | 5 (5.8%) | 1 (1.9%) | 1 (2.4%) |
| Cancer, n(%) | 9 (10.5%) | 1 (1.9%) | 3 (7.1%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 10 (11.6%) | 4 (7.7%) | 8 (19%) |
| HIV, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |  |

Demographics, HCQ (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=54) | SOC + HCQ (N=52) |
| **Demographics** |  |  |
| Age (years) | 59.9 (14.7) | 59.4 (13.4) |
| Female, n (%) | 23 (42.6%) | 15 (28.8%) |
| Body Mass Index (kg/m2) | 28 (5) | 28 (4) |
| Body Mass Index (kg/m2) | 28 (24 - 32) | 27 (25 - 30) |
| Symptoms prior to admission (days) | 8.6 (5.7) | 7.5 (4) |
| P/F-ratio at admittance (kPa) | 42 (14) | 40 (15) |
| P/F-ratio < 40kPa, n (%) | 23 (43.4%) | 25 (48.1%) |
| Temperature (°C) | 37.4 (0.9) | 37.4 (0.9) |
| Admitted to ward, n(%) | 53 (98.1%) | 47 (90.4%) |
| Admitted to ICU, n(%) | 1 (1.9%) | 5 (9.6%) |
| WHO Moderate disease state (4-5), n(%) | 52 (96.3%) | 48 (92.3%) |
| WHO Severe disease state (6-9), n(%) | 2 (3.7%) | 4 (7.7%) |
| WHO Severe disease state (6), n(%) | 1 (1.9%) | 2 (3.8%) |
| WHO Severe disease state (5), n(%) | 28 (51.9%) | 25 (48.1%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 7 (13.2%) | 9 (17.3%) |
| Chronic pulmonary disease, n(%) | 3 (5.7%) | 3 (5.8%) |
| Ever smoking, n(%) | 20 (37.7%) | 18 (34.6%) |
| Hypertension, n(%) | 15 (28.3%) | 18 (34.6%) |
| Diabetes, n(%) | 10 (18.9%) | 13 (25%) |
| Obese (BMI > 30 kg/m2), n(%) | 15 (30.6%) | 11 (24.4%) |
| **Co-medications** |  |  |
| Steroids | 3 (5.7%) | 3 (5.9%) |
| Other immunomodulatory drugs | 4 (7.5%) | 1 (2%) |
| ACE inhibitor | 1 (1.9%) | 6 (11.8%) |
| AT-II blockers | 9 (17%) | 9 (17.6%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 13.2 (12.1 - 14.1) | 13.4 (12.9 - 14.5) |
| WBC (x109/L) | 6.6 (4.7 - 9.6) | 6 (4.6 - 8.2) |
| Neutrophils (x109/L) | 4.8 (2.8 - 6.8) | 4.3 (3.2 - 5.6) |
| Lymphocytes (x109/L) | 1.2 (0.9 - 1.5) | 1 (0.8 - 1.3) |
| Platelet counts (x10^9/L) | 218 (160 - 293) | 186 (158 - 238) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 70 (47.8 - 159.2) | 61.5 (31.8 - 112) |
| Procalcitonin (µg/L) | 0.13 (0.1 - 0.24) | 0.1 (0.1 - 0.2) |
| Ferritin (µg/L) | 480 (239 - 1038) | 608 (276 - 1103.5) |
| **Other** |  |  |
| LDH (U/L) | 260 (209 - 347) | 275 (220.5 - 367.5) |
| D-dimer (mg/L FEU) | 0.85 (0.5 - 1.25) | 0.6 (0.41 - 1) |
| AST | 34.5 (26.2 - 53.8) | 43 (28 - 52) |
| ALT | 28 (19 - 47.8) | 36.5 (22 - 52.5) |
| eGFR (mL/min/1.73 m2) | 90.3 (80.1 - 105.6) | 85.7 (73.8 - 100.4) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 2 (1.6) | 2.2 (1.6) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| Zero converted (RBD ≤ 5) | 18 (51.4%) | 23 (62.2%) |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 123 (17) | 131 (17) |
| Diastolic Blood Pressure (mmHg) | 72 (11) | 77 (11) |
| Mean Arterial Blood Pressure (mmHg) | 89 (12) | 95 (12) |
| SOFA score | 1.6 (1.6) | 1.8 (2.1) |
| Chronic kidney disease, n(%) | 4 (7.5%) | 2 (3.8%) |
| Autoimmune disease, n(%) | 4 (7.5%) | 0 (0%) |
| Cognitive impairment/dementia, n(%) | 1 (1.9%) | 1 (1.9%) |
| Neurological disorder, n(%) | 4 (7.5%) | 1 (1.9%) |
| Cancer, n(%) | 4 (7.5%) | 1 (1.9%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 8 (15.1%) | 4 (7.7%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |

Demographics, Remdesivir (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=57) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |
| Age (years) | 58.6 (16.4) | 61.4 (16.1) |
| Female, n (%) | 20 (35.1%) | 13 (31%) |
| Body Mass Index (kg/m2) | 28 (5) | 28 (5) |
| Body Mass Index (kg/m2) | 28 (24 - 32) | 27 (25 - 30) |
| Symptoms prior to admission (days) | 7.8 (6.2) | 7.9 (3.2) |
| P/F-ratio at admittance (kPa) | 39 (14) | 44 (10) |
| P/F-ratio < 40kPa, n (%) | 27 (47.4%) | 13 (31.7%) |
| Temperature (°C) | 37.6 (1) | 37.4 (0.9) |
| Admitted to ward, n(%) | 54 (94.7%) | 40 (95.2%) |
| Admitted to ICU, n(%) | 3 (5.3%) | 2 (4.8%) |
| WHO Moderate disease state (4-5), n(%) | 55 (96.5%) | 39 (92.9%) |
| WHO Severe disease state (6-9), n(%) | 2 (3.5%) | 3 (7.1%) |
| WHO Severe disease state (6), n(%) | NA | 2 (4.8%) |
| WHO Severe disease state (5), n(%) | 35 (61.4%) | 14 (33.3%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 7 (12.3%) | 9 (21.4%) |
| Chronic pulmonary disease, n(%) | 4 (7%) | 1 (2.4%) |
| Ever smoking, n(%) | 22 (38.6%) | 19 (45.2%) |
| Hypertension, n(%) | 19 (33.3%) | 10 (23.8%) |
| Diabetes, n(%) | 12 (21.1%) | 3 (7.1%) |
| Obese (BMI > 30 kg/m2), n(%) | 17 (31.5%) | 9 (23.1%) |
| **Co-medications** |  |  |
| Steroids | 1 (1.8%) | 2 (4.8%) |
| Other immunomodulatory drugs | 2 (3.5%) | 2 (4.8%) |
| ACE inhibitor | 3 (5.3%) | 2 (4.8%) |
| AT-II blockers | 9 (15.8%) | 8 (19%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 13.1 (12.3 - 13.7) | 13.1 (12 - 13.9) |
| WBC (x109/L) | 6.6 (5.1 - 9.4) | 5.8 (4.7 - 7.4) |
| Neutrophils (x109/L) | 5 (3.2 - 7.2) | 4 (2.5 - 6.5) |
| Lymphocytes (x109/L) | 1.1 (0.9 - 1.3) | 1 (0.8 - 1.6) |
| Platelet counts (x10^9/L) | 215 (168.8 - 290.2) | 176 (156 - 279) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 106.5 (56.8 - 153.5) | 64.5 (29.2 - 129) |
| Procalcitonin (µg/L) | 0.16 (0.1 - 0.29) | 0.12 (0.1 - 0.2) |
| Ferritin (µg/L) | 563 (311.5 - 1218) | 677 (442 - 1488) |
| **Other** |  |  |
| LDH (U/L) | 281.5 (229 - 363.5) | 287 (214.8 - 361) |
| D-dimer (mg/L FEU) | 0.76 (0.58 - 1.18) | 0.8 (0.44 - 1.04) |
| AST | 42 (29.5 - 73.5) | 46 (27 - 63.5) |
| ALT | 32.5 (18.8 - 74.5) | 32 (22 - 62.5) |
| eGFR (mL/min/1.73 m2) | 87.9 (68 - 106.1) | 90.8 (76.9 - 105.1) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 1.8 (1.6) | 2 (1.7) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| Zero converted (RBD ≤ 5) | 24 (55.8%) | 10 (35.7%) |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 123 (17) | 121 (18) |
| Diastolic Blood Pressure (mmHg) | 72 (10) | 72 (13) |
| Mean Arterial Blood Pressure (mmHg) | 89 (11) | 88 (13) |
| SOFA score | 1.7 (1.7) | 1.3 (1.3) |
| Chronic kidney disease, n(%) | 5 (8.8%) | 3 (7.1%) |
| Autoimmune disease, n(%) | 2 (3.5%) | 3 (7.1%) |
| Cognitive impairment/dementia, n(%) | 3 (5.3%) | 0 (0%) |
| Neurological disorder, n(%) | 3 (5.3%) | 1 (2.4%) |
| Cancer, n(%) | 7 (12.3%) | 3 (7.1%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 7 (12.3%) | 8 (19%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |

Missing values, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 0 (0%) | 0 (0%) | 0 (0%) |
| Female, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Body Mass Index (kg/m2) | 7 (8%), 7 (8%) | 7 (13.5%), 7 (13.5%) | 3 (7.1%), 3 (7.1%) |
| Symptoms prior to admission (days) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| P/F-ratio at admittance (kPa) | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| P/F-ratio < 40kPa, n (%) | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| Temperature (°C) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ward, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ICU, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Moderate disease state (4-5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6-9), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Chronic pulmonary disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Ever smoking, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Hypertension, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Diabetes, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Obese (BMI > 30 kg/m2), n(%) | 7 (8%) | 7 (13.5%) | 3 (7.1%) |
| **Co-medications** |  |  |  |
| Steroids | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| Other immunomodulatory drugs | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| ACE inhibitor | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| AT-II blockers | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 1 (1.1%) | 0 (0%) | 2 (4.8%) |
| WBC (x109/L) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Neutrophils (x109/L) | 3 (3.4%) | 2 (3.8%) | 5 (11.9%) |
| Lymphocytes (x109/L) | 2 (2.3%) | 2 (3.8%) | 5 (11.9%) |
| Platelet counts (x10^9/L) | 1 (1.1%) | 1 (1.9%) | 1 (2.4%) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 2 (2.3%) | 0 (0%) | 0 (0%) |
| Procalcitonin (µg/L) | 23 (26.4%) | 19 (36.5%) | 16 (38.1%) |
| Ferritin (µg/L) | 3 (3.4%) | 5 (9.6%) | 1 (2.4%) |
| **Other** |  |  |  |
| LDH (U/L) | 1 (1.1%) | 5 (9.6%) | 2 (4.8%) |
| D-dimer (mg/L FEU) | 8 (9.2%) | 7 (13.5%) | 4 (9.5%) |
| AST | 6 (6.9%) | 3 (5.8%) | 2 (4.8%) |
| ALT | 6 (6.9%) | 2 (3.8%) | 0 (0%) |
| eGFR (mL/min/1.73 m2) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 20 (23%) | 12 (23.1%) | 9 (21.4%) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| Zero converted (RBD ≤ 5) | 25 (28.7%) | 15 (28.8%) | 14 (33.3%) |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Diastolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Mean Arterial Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| SOFA score | 5 (5.7%) | 5 (9.6%) | 1 (2.4%) |
| Chronic kidney disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Autoimmune disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cognitive impairment/dementia, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Neurological disorder, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cancer, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cirrhosis, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| HIV, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |  |

# Exposure

Exposure to study treatment

|  |  |  |
| --- | --- | --- |
| Parameter | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Total dose (mg), median (IQR) | 4400 (1100 - 7600) | 2800 (700 - 5258) |
| Treatment duration, median (IQR) | 6 (4 - 9) | 4 (3 - 7) |
| Number of doses given, median (IQR) | 7 (4 - 10) | 6 (4 - 8) |
| Patients with any treatment discrepencies, n (%) | 9 (29%) | 6 (33.3%) |

# Efficacy

## Mortality

### Descriptives

All arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 5 | 87 | 5.7 |
| Hydroxychloroquine + SOC | 5 | 52 | 9.6 |
| Remdesivir + SOC | 2 | 42 | 4.8 |










HCQ (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 2 | 54 | 3.7 |
| Hydroxychloroquine + SOC | 5 | 52 | 9.6 |

Remdesivir (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 4 | 57 | 7.0 |
| Remdesivir + SOC | 2 | 42 | 4.8 |

### Plots




### Efficacy estimates

Relative risk estimates and p-values


|  |  |  |
| --- | --- | --- |
| Timeframe, Population | Relative risk | P-value |
| Full timeframe, All | Not applicable | 0.574 |
| Full timeframe, Hydroxychloroquine only | 2.58 (95% CI 0.59 to 11.37) | 0.211 |
| Full timeframe, Remdesivir only | 0.69 (95% CI 0.14 to 3.5) | 0.655 |
| Censored at 60 days, All | Not applicable | 0.825 |
| Censored at 60 days, Hydroxychloroquine only | 2.12 (95% CI 0.43 to 10.5) | 0.359 |
| Censored at 60 days, Remdesivir only | 0.69 (95% CI 0.14 to 3.5) | 0.655 |
| Censored at 28 days, All | Not applicable | 0.949 |
| Censored at 28 days, Hydroxychloroquine only | 2.88 (95% CI 0.4 to 20.44) | 0.291 |
| Censored at 28 days, Remdesivir only | 0.69 (95% CI 0.14 to 3.5) | 0.655 |

## Viral load



Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope by treatment | -0.177 | -0.249 | -0.104 | 0.000 |
| Remdesivir + SOC | Slope by treatment | -0.192 | -0.275 | -0.109 | 0.000 |
| Remdesivir + SOC | Difference in slope | -0.015 | -0.125 | 0.095 | 0.788 |



Estimated treatment effect, HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope by treatment | -0.148 | -0.239 | -0.057 | 0.001 |
| Hydroxychloroquine + SOC | Slope by treatment | -0.270 | -0.361 | -0.180 | 0.000 |
| Hydroxychloroquine + SOC | Difference in slope | -0.122 | -0.251 | 0.006 | 0.062 |

## Dichotomous endpoints

### Descriptives

Hydroxycholoquine

|  |  |  |
| --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC |
| Mortality during hospitalisation | 2 (3.7%) | 5 (9.6%) |
| Mortality (censored at day 28) | 1 (1.9%) | 3 (5.8%) |
| Mortality (censored at day 60) | 2 (3.7%) | 4 (7.7%) |
| WHO disease state progression | 11 (20.4%) | 11 (21.2%) |
| WHO disease state progression (censoreda at day 28) | 11 (20.4%) | 11 (21.2%) |
| WHO disease state progression (censoreda at day 60) | 11 (20.4%) | 11 (21.2%) |
| Mechanical ventilation during hospitalisation | 6 (11.1%) | 8 (15.4%) |
| Mechanical ventilation (censored at day 28) | 6 (11.1%) | 8 (15.4%) |
| Mechanical ventilation (censored at day 60) | 6 (11.1%) | 8 (15.4%) |
| Admission to ICU during hospitalisation | 11 (20.4%) | 14 (26.9%) |
| Admission to ICU (censored at day 28) | 11 (20.4%) | 14 (26.9%) |
| Admission to ICU (censored at day 60) | 11 (20.4%) | 14 (26.9%) |

Figures are number of patients with the outcome and percent (%)

Remdesivir

|  |  |  |
| --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC |
| Mortality during hospitalisation | 4 (7%) | 2 (4.8%) |
| Mortality (censored at day 28) | 4 (7%) | 2 (4.8%) |
| Mortality (censored at day 60) | 4 (7%) | 2 (4.8%) |
| WHO disease state progression | 11 (19.3%) | 5 (11.9%) |
| WHO disease state progression (censoreda at day 28) | 11 (19.3%) | 5 (11.9%) |
| WHO disease state progression (censoreda at day 60) | 11 (19.3%) | 5 (11.9%) |
| Mechanical ventilation during hospitalisation | 7 (12.3%) | 2 (4.8%) |
| Mechanical ventilation (censored at day 28) | 7 (12.3%) | 2 (4.8%) |
| Mechanical ventilation (censored at day 60) | 7 (12.3%) | 2 (4.8%) |
| Admission to ICU during hospitalisation | 12 (21.1%) | 4 (9.5%) |
| Admission to ICU (censored at day 28) | 12 (21.1%) | 4 (9.5%) |
| Admission to ICU (censored at day 60) | 12 (21.1%) | 4 (9.5%) |

Figures are number of patients with the outcome and percent (%)

### Marginal probability estimates by treatment group and difference

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC | Estimated marginal treatment effect |
| Mortality during hospitalisation | 3.7% (-1.3 to 8.7) | 9.6% (1.6 to 17.6) | 5.9% (-3.6 to 15.4) |
| Mortality (censored at day 28) | 1.9% (-1.7 to 5.4) | 5.8% (-0.6 to 12.1) | 3.9% (-3.4 to 11.2) |
| Mortality (censored at day 60) | 3.7% (-1.3 to 8.7) | 7.7% (0.4 to 14.9) | 4% (-4.8 to 12.8) |
| WHO disease state progression | 20.4% (9.6 to 31.1) | 21.2% (10.1 to 32.3) | 0.8% (-14.7 to 16.2) |
| WHO disease state progression (censoreda at day 28) | 20.4% (9.6 to 31.1) | 21.2% (10.1 to 32.3) | 0.8% (-14.7 to 16.2) |
| WHO disease state progression (censoreda at day 60) | 20.4% (9.6 to 31.1) | 21.2% (10.1 to 32.3) | 0.8% (-14.7 to 16.2) |
| Mechanical ventilation during hospitalisation | 11.1% (2.7 to 19.5) | 15.4% (5.6 to 25.2) | 4.3% (-8.6 to 17.2) |
| Mechanical ventilation (censored at day 28) | 11.1% (2.7 to 19.5) | 15.4% (5.6 to 25.2) | 4.3% (-8.6 to 17.2) |
| Mechanical ventilation (censored at day 60) | 11.1% (2.7 to 19.5) | 15.4% (5.6 to 25.2) | 4.3% (-8.6 to 17.2) |
| Admission to ICU during hospitalisation | 20.4% (9.6 to 31.1) | 26.9% (14.9 to 39) | 6.6% (-9.6 to 22.7) |
| Admission to ICU (censored at day 28) | 20.4% (9.6 to 31.1) | 26.9% (14.9 to 39) | 6.6% (-9.6 to 22.7) |
| Admission to ICU (censored at day 60) | 20.4% (9.6 to 31.1) | 26.9% (14.9 to 39) | 6.6% (-9.6 to 22.7) |

Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC | Estimated marginal treatment effect |
| Mortality during hospitalisation | 7% (0.4 to 13.6) | 4.8% (-1.7 to 11.2) | -2.3% (-11.5 to 7) |
| Mortality (censored at day 28) | 7% (0.4 to 13.6) | 4.8% (-1.7 to 11.2) | -2.3% (-11.5 to 7) |
| Mortality (censored at day 60) | 7% (0.4 to 13.6) | 4.8% (-1.7 to 11.2) | -2.3% (-11.5 to 7) |
| WHO disease state progression | 19.3% (9.1 to 29.5) | 11.9% (2.1 to 21.7) | -7.4% (-21.6 to 6.8) |
| WHO disease state progression (censoreda at day 28) | 19.3% (9.1 to 29.5) | 11.9% (2.1 to 21.7) | -7.4% (-21.6 to 6.8) |
| WHO disease state progression (censoreda at day 60) | 19.3% (9.1 to 29.5) | 11.9% (2.1 to 21.7) | -7.4% (-21.6 to 6.8) |
| Mechanical ventilation during hospitalisation | 12.3% (3.8 to 20.8) | 4.8% (-1.7 to 11.2) | -7.5% (-18.2 to 3.2) |
| Mechanical ventilation (censored at day 28) | 12.3% (3.8 to 20.8) | 4.8% (-1.7 to 11.2) | -7.5% (-18.2 to 3.2) |
| Mechanical ventilation (censored at day 60) | 12.3% (3.8 to 20.8) | 4.8% (-1.7 to 11.2) | -7.5% (-18.2 to 3.2) |
| Admission to ICU during hospitalisation | 21.1% (10.5 to 31.6) | 9.5% (0.6 to 18.4) | -11.5% (-25.3 to 2.3) |
| Admission to ICU (censored at day 28) | 21.1% (10.5 to 31.6) | 9.5% (0.6 to 18.4) | -11.5% (-25.3 to 2.3) |
| Admission to ICU (censored at day 60) | 21.1% (10.5 to 31.6) | 9.5% (0.6 to 18.4) | -11.5% (-25.3 to 2.3) |

## Inflammatory laboratory parameters

### Descriptives

CRP (mg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 104.82 (83.35) | 81.71 (66.1) |
| 0 days | Median [IQR] | 70 [47.75 - 159.25] | 61.5 [31.75 - 112] |
| 0 days | Missing / Non-Missing | 2 / 52 | 0 / 52 |
| 1 days | Mean (SD) | 106.69 (80.54) | 95.14 (76.73) |
| 1 days | Median [IQR] | 88.5 [42 - 170.75] | 78 [44.5 - 133] |
| 1 days | Missing / Non-Missing | 12 / 42 | 8 / 44 |
| 2 days | Mean (SD) | 104.25 (86.57) | 89.43 (77.6) |
| 2 days | Median [IQR] | 86 [46 - 130] | 67 [35 - 127.75] |
| 2 days | Missing / Non-Missing | 5 / 45 | 7 / 44 |
| 3 days | Mean (SD) | 96.42 (84.44) | 89.62 (62.96) |
| 3 days | Median [IQR] | 74 [26.5 - 134.25] | 72 [33.75 - 132.25] |
| 3 days | Missing / Non-Missing | 6 / 38 | 5 / 40 |
| 4 days | Mean (SD) | 104.96 (86.68) | 93.61 (64.45) |
| 4 days | Median [IQR] | 90 [44 - 145] | 92.5 [40 - 131.5] |
| 4 days | Missing / Non-Missing | 5 / 33 | 7 / 34 |
| 5 days | Mean (SD) | 92.69 (81.28) | 95.82 (78.64) |
| 5 days | Median [IQR] | 70 [34 - 148] | 68 [39 - 130] |
| 5 days | Missing / Non-Missing | 5 / 29 | 4 / 33 |
| 6 days | Mean (SD) | 85.95 (81.09) | 95.45 (86.95) |
| 6 days | Median [IQR] | 57 [24.5 - 116] | 63 [36.5 - 142.5] |
| 6 days | Missing / Non-Missing | 0 / 31 | 6 / 27 |
| 7 days | Mean (SD) | 84.47 (84.32) | 107.83 (88.24) |
| 7 days | Median [IQR] | 63.5 [14.25 - 103.75] | 100.5 [26.5 - 167.25] |
| 7 days | Missing / Non-Missing | 1 / 26 | 3 / 24 |
| 8 days | Mean (SD) | 93.07 (90.34) | 94.18 (84.54) |
| 8 days | Median [IQR] | 47.5 [28.5 - 165] | 61.5 [28 - 156.75] |
| 8 days | Missing / Non-Missing | 1 / 22 | 3 / 22 |
| 9 days | Mean (SD) | 87.63 (88.83) | 95.72 (70.67) |
| 9 days | Median [IQR] | 43 [18.25 - 155.25] | 83 [40.25 - 162.25] |
| 9 days | Missing / Non-Missing | 2 / 18 | 5 / 18 |
| 10 days | Mean (SD) | 72.49 (89.35) | 65.65 (63.18) |
| 10 days | Median [IQR] | 18 [12 - 106] | 33 [12 - 122] |
| 10 days | Missing / Non-Missing | 4 / 13 | 4 / 17 |
| 11 days | Mean (SD) | 74.2 (78.39) | 72.57 (81.65) |
| 11 days | Median [IQR] | 60.5 [10.5 - 103.25] | 52 [13 - 107] |
| 11 days | Missing / Non-Missing | 4 / 12 | 2 / 15 |
| 12 days | Mean (SD) | 72.55 (80.66) | 89.64 (65.42) |
| 12 days | Median [IQR] | 44 [7.9 - 107] | 89 [30.5 - 138.5] |
| 12 days | Missing / Non-Missing | 4 / 11 | 4 / 11 |
| 13 days | Mean (SD) | 117.87 (83.72) | 83.79 (86.47) |
| 13 days | Median [IQR] | 106 [54 - 187] | 60.5 [10.25 - 111.5] |
| 13 days | Missing / Non-Missing | 5 / 9 | 1 / 14 |
| 14 days | Mean (SD) | 73.81 (94.77) | 80.58 (109.08) |
| 14 days | Median [IQR] | 24 [18 - 81] | 24 [11.25 - 107] |
| 14 days | Missing / Non-Missing | 1 / 9 | 1 / 8 |

CRP (mg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 108.71 (66.52) | 79.17 (59.24) |
| 0 days | Median [IQR] | 106.5 [56.75 - 153.5] | 64.5 [29.25 - 129] |
| 0 days | Missing / Non-Missing | 1 / 56 | 0 / 42 |
| 1 days | Mean (SD) | 107.49 (68.4) | 82.35 (58.49) |
| 1 days | Median [IQR] | 90 [56.5 - 147.5] | 71.5 [43.5 - 107.5] |
| 1 days | Missing / Non-Missing | 10 / 47 | 5 / 36 |
| 2 days | Mean (SD) | 96.45 (80.56) | 73.41 (58) |
| 2 days | Median [IQR] | 76 [44.5 - 120.5] | 59 [29 - 99.5] |
| 2 days | Missing / Non-Missing | 9 / 47 | 1 / 39 |
| 3 days | Mean (SD) | 89.98 (81.69) | 76.68 (67.37) |
| 3 days | Median [IQR] | 69 [41 - 120] | 64 [26 - 98.75] |
| 3 days | Missing / Non-Missing | 10 / 41 | 4 / 32 |
| 4 days | Mean (SD) | 87.54 (84.29) | 75.26 (90.57) |
| 4 days | Median [IQR] | 70.5 [37.5 - 104.75] | 43.5 [20.25 - 87.25] |
| 4 days | Missing / Non-Missing | 5 / 36 | 3 / 28 |
| 5 days | Mean (SD) | 66.27 (64.15) | 85.82 (88.82) |
| 5 days | Median [IQR] | 45.5 [21.5 - 91] | 55 [15 - 106] |
| 5 days | Missing / Non-Missing | 7 / 32 | 5 / 21 |
| 6 days | Mean (SD) | 73.86 (73.89) | 66.39 (65.45) |
| 6 days | Median [IQR] | 48 [16.75 - 101] | 48 [11.08 - 104.25] |
| 6 days | Missing / Non-Missing | 6 / 30 | 2 / 20 |
| 7 days | Mean (SD) | 64.24 (63.19) | 58.07 (49.44) |
| 7 days | Median [IQR] | 38 [11.25 - 100] | 48.5 [22.5 - 79.25] |
| 7 days | Missing / Non-Missing | 2 / 30 | 2 / 16 |
| 8 days | Mean (SD) | 80.67 (83.25) | 49.12 (34.88) |
| 8 days | Median [IQR] | 49 [19.5 - 124] | 42 [22.5 - 79.5] |
| 8 days | Missing / Non-Missing | 3 / 24 | 4 / 11 |
| 9 days | Mean (SD) | 75.6 (82.18) | 29.26 (33.37) |
| 9 days | Median [IQR] | 43 [17.25 - 117.5] | 12 [3.65 - 44.5] |
| 9 days | Missing / Non-Missing | 2 / 20 | 2 / 11 |
| 10 days | Mean (SD) | 63.4 (75.24) | 26.22 (27.84) |
| 10 days | Median [IQR] | 18 [13.5 - 113.5] | 18.55 [4.35 - 34.25] |
| 10 days | Missing / Non-Missing | 4 / 15 | 0 / 10 |
| 11 days | Mean (SD) | 77.03 (115.56) | 40.5 (24.45) |
| 11 days | Median [IQR] | 17 [9 - 107] | 41.5 [31 - 52.75] |
| 11 days | Missing / Non-Missing | 4 / 13 | 2 / 6 |
| 12 days | Mean (SD) | 92.41 (188.13) | 28.6 (28.59) |
| 12 days | Median [IQR] | 11 [6.4 - 88] | 19 [5 - 42] |
| 12 days | Missing / Non-Missing | 5 / 11 | 1 / 5 |
| 13 days | Mean (SD) | 75.18 (104.7) | 30.33 (16.01) |
| 13 days | Median [IQR] | 44.5 [11.5 - 86.5] | 31 [22.5 - 38.5] |
| 13 days | Missing / Non-Missing | 4 / 10 | 1 / 3 |
| 14 days | Mean (SD) | 38.46 (48.82) | 25.53 (16.63) |
| 14 days | Median [IQR] | 19 [8.93 - 43.5] | 32 [22.03 - 35.5] |
| 14 days | Missing / Non-Missing | 1 / 10 | 0 / 4 |

Ferritin (µg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 749.55 (720.33) | 744.28 (582.02) |
| 0 days | Median [IQR] | 480 [239 - 1038] | 608 [276 - 1103.5] |
| 0 days | Missing / Non-Missing | 1 / 53 | 5 / 47 |
| 1 days | Mean (SD) | 962.1 (820.33) | 869.78 (530.91) |
| 1 days | Median [IQR] | 683 [397 - 1118] | 767 [385 - 1209] |
| 1 days | Missing / Non-Missing | 24 / 30 | 15 / 37 |
| 2 days | Mean (SD) | 820.2 (695.02) | 959.5 (702.21) |
| 2 days | Median [IQR] | 586 [273 - 1120] | 1028.5 [368.75 - 1326.5] |
| 2 days | Missing / Non-Missing | 9 / 41 | 11 / 40 |
| 3 days | Mean (SD) | 1171.87 (1030.2) | 902.72 (662.04) |
| 3 days | Median [IQR] | 884 [282.75 - 1768.75] | 842 [397 - 1212.5] |
| 3 days | Missing / Non-Missing | 14 / 30 | 10 / 35 |
| 4 days | Mean (SD) | 1463.46 (1672.36) | 1180.1 (698.66) |
| 4 days | Median [IQR] | 865.5 [418.75 - 1936] | 1070 [667 - 1546] |
| 4 days | Missing / Non-Missing | 14 / 24 | 12 / 29 |
| 5 days | Mean (SD) | 1210.05 (1365.82) | 1108.18 (651.93) |
| 5 days | Median [IQR] | 667 [365.5 - 1691] | 951 [642.25 - 1327.25] |
| 5 days | Missing / Non-Missing | 15 / 19 | 9 / 28 |
| 6 days | Mean (SD) | 1281.85 (1219.43) | 975.69 (561.6) |
| 6 days | Median [IQR] | 896 [498 - 1642] | 872.5 [678.75 - 1187.25] |
| 6 days | Missing / Non-Missing | 4 / 27 | 7 / 26 |
| 7 days | Mean (SD) | 1130.2 (752.46) | 1159 (654.58) |
| 7 days | Median [IQR] | 944 [628.75 - 1535.75] | 1033 [735 - 1366.5] |
| 7 days | Missing / Non-Missing | 7 / 20 | 4 / 23 |
| 8 days | Mean (SD) | 850.47 (643.2) | 1053.4 (647.06) |
| 8 days | Median [IQR] | 713 [243 - 1209] | 812 [617 - 1393] |
| 8 days | Missing / Non-Missing | 4 / 19 | 10 / 15 |
| 9 days | Mean (SD) | 973.14 (704.68) | 993.35 (648.58) |
| 9 days | Median [IQR] | 1016 [326.75 - 1559.75] | 746 [508 - 1251] |
| 9 days | Missing / Non-Missing | 6 / 14 | 6 / 17 |
| 10 days | Mean (SD) | 1044 (850.91) | 1048.46 (536.31) |
| 10 days | Median [IQR] | 954 [363.5 - 1559.5] | 899 [784 - 1361] |
| 10 days | Missing / Non-Missing | 6 / 11 | 8 / 13 |
| 11 days | Mean (SD) | 924.64 (1036.71) | 949.89 (731.93) |
| 11 days | Median [IQR] | 800 [169.5 - 1052] | 728 [584 - 1112] |
| 11 days | Missing / Non-Missing | 5 / 11 | 8 / 9 |
| 12 days | Mean (SD) | 1187 (1155.17) | 648.14 (234.03) |
| 12 days | Median [IQR] | 1068 [174 - 1533] | 664 [578.5 - 714] |
| 12 days | Missing / Non-Missing | 6 / 9 | 8 / 7 |
| 13 days | Mean (SD) | 1266.57 (936.99) | 682.82 (480.73) |
| 13 days | Median [IQR] | 1160 [587 - 1764.5] | 598 [470 - 863] |
| 13 days | Missing / Non-Missing | 7 / 7 | 4 / 11 |
| 14 days | Mean (SD) | 853.57 (631.24) | 645.2 (716.78) |
| 14 days | Median [IQR] | 698 [362 - 1335.5] | 397 [392 - 553] |
| 14 days | Missing / Non-Missing | 3 / 7 | 4 / 5 |

Ferritin (µg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 1332.65 (3204.54) | 1048.29 (879.59) |
| 0 days | Median [IQR] | 563 [311.5 - 1218] | 677 [442 - 1488] |
| 0 days | Missing / Non-Missing | 3 / 54 | 1 / 41 |
| 1 days | Mean (SD) | 1548.54 (3142.56) | 1020.27 (885.43) |
| 1 days | Median [IQR] | 880 [397.5 - 1451] | 769.5 [510.25 - 1080.75] |
| 1 days | Missing / Non-Missing | 22 / 35 | 19 / 22 |
| 2 days | Mean (SD) | 1166.1 (1837.36) | 1067.97 (798.91) |
| 2 days | Median [IQR] | 603.5 [383.5 - 1277] | 909 [545.5 - 1226.75] |
| 2 days | Missing / Non-Missing | 16 / 40 | 6 / 34 |
| 3 days | Mean (SD) | 1128.94 (785.77) | 1215.85 (959.44) |
| 3 days | Median [IQR] | 940 [575 - 1754.5] | 948 [485 - 1737] |
| 3 days | Missing / Non-Missing | 19 / 32 | 9 / 27 |
| 4 days | Mean (SD) | 1066.56 (970.7) | 1463.86 (952.38) |
| 4 days | Median [IQR] | 638 [489 - 1206] | 1232.5 [786.75 - 1906.75] |
| 4 days | Missing / Non-Missing | 16 / 25 | 9 / 22 |
| 5 days | Mean (SD) | 1067.57 (827.36) | 1247.3 (756.44) |
| 5 days | Median [IQR] | 872 [489 - 1322] | 943 [705 - 1627] |
| 5 days | Missing / Non-Missing | 18 / 21 | 9 / 17 |
| 6 days | Mean (SD) | 908.36 (638.77) | 1138.18 (820.12) |
| 6 days | Median [IQR] | 710 [419 - 1462] | 919 [739 - 1332] |
| 6 days | Missing / Non-Missing | 11 / 25 | 5 / 17 |
| 7 days | Mean (SD) | 998 (931.84) | 1235.87 (799.31) |
| 7 days | Median [IQR] | 707 [413 - 1446] | 1255 [799.5 - 1415.5] |
| 7 days | Missing / Non-Missing | 7 / 25 | 3 / 15 |
| 8 days | Mean (SD) | 942.1 (1018.34) | 1106.6 (822.67) |
| 8 days | Median [IQR] | 691 [375.75 - 1157.5] | 834 [745.75 - 997.25] |
| 8 days | Missing / Non-Missing | 7 / 20 | 5 / 10 |
| 9 days | Mean (SD) | 666.2 (508.9) | 747.56 (523.32) |
| 9 days | Median [IQR] | 456 [316.5 - 952] | 744 [506 - 861] |
| 9 days | Missing / Non-Missing | 7 / 15 | 4 / 9 |
| 10 days | Mean (SD) | 761 (555.87) | 789.86 (434.71) |
| 10 days | Median [IQR] | 612 [389 - 1113] | 728 [612.5 - 933] |
| 10 days | Missing / Non-Missing | 6 / 13 | 3 / 7 |
| 11 days | Mean (SD) | 757.33 (821.49) | 850.5 (510.72) |
| 11 days | Median [IQR] | 566.5 [181.75 - 973.75] | 615 [562.75 - 902.75] |
| 11 days | Missing / Non-Missing | 5 / 12 | 4 / 4 |
| 12 days | Mean (SD) | 883.11 (1000.46) | 644.33 (35.85) |
| 12 days | Median [IQR] | 839 [174 - 1068] | 663 [633 - 665] |
| 12 days | Missing / Non-Missing | 7 / 9 | 3 / 3 |
| 13 days | Mean (SD) | 873.78 (578.45) | 677.33 (46.74) |
| 13 days | Median [IQR] | 723 [358 - 1160] | 665 [651.5 - 697] |
| 13 days | Missing / Non-Missing | 5 / 9 | 1 / 3 |
| 14 days | Mean (SD) | 685.33 (567.83) | 671 (83.86) |
| 14 days | Median [IQR] | 396 [257 - 1126] | 634 [623 - 700.5] |
| 14 days | Missing / Non-Missing | 2 / 9 | 1 / 3 |

LDH (U/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 290.43 (130.76) | 311.81 (138.59) |
| 0 days | Median [IQR] | 260 [209 - 347] | 275 [220.5 - 367.5] |
| 0 days | Missing / Non-Missing | 1 / 53 | 5 / 47 |
| 1 days | Mean (SD) | 310.54 (139) | 334.67 (145.15) |
| 1 days | Median [IQR] | 278 [203.25 - 374.5] | 311 [233 - 392] |
| 1 days | Missing / Non-Missing | 28 / 26 | 19 / 33 |
| 2 days | Mean (SD) | 307.62 (123.11) | 332.68 (157.5) |
| 2 days | Median [IQR] | 298 [208 - 374] | 294.5 [226.75 - 391.25] |
| 2 days | Missing / Non-Missing | 13 / 37 | 17 / 34 |
| 3 days | Mean (SD) | 342.08 (137.77) | 341.31 (167.89) |
| 3 days | Median [IQR] | 332 [240 - 441] | 321 [218 - 437] |
| 3 days | Missing / Non-Missing | 17 / 27 | 13 / 32 |
| 4 days | Mean (SD) | 359.38 (133.65) | 393.16 (183.41) |
| 4 days | Median [IQR] | 304 [256 - 488] | 351 [261 - 480] |
| 4 days | Missing / Non-Missing | 17 / 21 | 16 / 25 |
| 5 days | Mean (SD) | 353.63 (127.07) | 401.27 (176.76) |
| 5 days | Median [IQR] | 332 [282.5 - 442.5] | 326 [279.25 - 525.75] |
| 5 days | Missing / Non-Missing | 15 / 19 | 15 / 22 |
| 6 days | Mean (SD) | 302.29 (112.53) | 354.63 (151.29) |
| 6 days | Median [IQR] | 288.5 [240.5 - 375.25] | 279 [270.5 - 442] |
| 6 days | Missing / Non-Missing | 7 / 24 | 14 / 19 |
| 7 days | Mean (SD) | 303.72 (86.25) | 338.86 (108.52) |
| 7 days | Median [IQR] | 281.5 [253.75 - 359.25] | 293 [239 - 400] |
| 7 days | Missing / Non-Missing | 9 / 18 | 6 / 21 |
| 8 days | Mean (SD) | 282.44 (79.75) | 369.69 (92.84) |
| 8 days | Median [IQR] | 266.5 [229 - 331.75] | 336 [289 - 410] |
| 8 days | Missing / Non-Missing | 7 / 16 | 12 / 13 |
| 9 days | Mean (SD) | 307.46 (73.96) | 370.17 (125.18) |
| 9 days | Median [IQR] | 286 [281 - 356] | 357 [303.25 - 395] |
| 9 days | Missing / Non-Missing | 9 / 11 | 11 / 12 |
| 10 days | Mean (SD) | 274.45 (88.55) | 337 (95.56) |
| 10 days | Median [IQR] | 258 [213 - 374] | 340 [284.75 - 369.75] |
| 10 days | Missing / Non-Missing | 8 / 9 | 9 / 12 |
| 11 days | Mean (SD) | 279.22 (93.29) | 290.83 (76.81) |
| 11 days | Median [IQR] | 252 [240 - 360] | 267.5 [260 - 298.25] |
| 11 days | Missing / Non-Missing | 7 / 9 | 11 / 6 |
| 12 days | Mean (SD) | 298.45 (118.8) | 318.72 (57.5) |
| 12 days | Median [IQR] | 269 [215 - 366] | 307 [277 - 357.5] |
| 12 days | Missing / Non-Missing | 6 / 9 | 8 / 7 |
| 13 days | Mean (SD) | 262.5 (111.87) | 279.63 (107.99) |
| 13 days | Median [IQR] | 247 [182.25 - 320.75] | 268.5 [217 - 325.25] |
| 13 days | Missing / Non-Missing | 8 / 6 | 7 / 8 |
| 14 days | Mean (SD) | 286.13 (106.76) | 305.2 (125.07) |
| 14 days | Median [IQR] | 308 [206.25 - 358] | 294 [254 - 348] |
| 14 days | Missing / Non-Missing | 2 / 8 | 4 / 5 |

LDH (U/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 320.63 (143.26) | 297.78 (103.02) |
| 0 days | Median [IQR] | 281.5 [229 - 363.5] | 287 [214.75 - 361] |
| 0 days | Missing / Non-Missing | 1 / 56 | 2 / 40 |
| 1 days | Mean (SD) | 342.3 (139.87) | 271.33 (60.68) |
| 1 days | Median [IQR] | 311 [243.5 - 413.5] | 270 [243 - 302] |
| 1 days | Missing / Non-Missing | 30 / 27 | 20 / 21 |
| 2 days | Mean (SD) | 320.33 (126.34) | 312.52 (95.06) |
| 2 days | Median [IQR] | 301 [233 - 380] | 310 [239 - 361] |
| 2 days | Missing / Non-Missing | 23 / 33 | 11 / 29 |
| 3 days | Mean (SD) | 331.5 (116.96) | 351.56 (169.8) |
| 3 days | Median [IQR] | 319.5 [263.5 - 380] | 287 [230 - 422] |
| 3 days | Missing / Non-Missing | 21 / 30 | 11 / 25 |
| 4 days | Mean (SD) | 335.52 (117.82) | 324.9 (125.07) |
| 4 days | Median [IQR] | 300 [264.5 - 354] | 282.5 [241.25 - 384] |
| 4 days | Missing / Non-Missing | 18 / 23 | 11 / 20 |
| 5 days | Mean (SD) | 342.42 (112.42) | 304.63 (91.8) |
| 5 days | Median [IQR] | 300 [275 - 397.5] | 278 [238.25 - 370.25] |
| 5 days | Missing / Non-Missing | 20 / 19 | 10 / 16 |
| 6 days | Mean (SD) | 315.2 (113.45) | 262.67 (67.14) |
| 6 days | Median [IQR] | 286.5 [251.75 - 353] | 263 [208 - 303.5] |
| 6 days | Missing / Non-Missing | 16 / 20 | 7 / 15 |
| 7 days | Mean (SD) | 282.96 (112.47) | 245.58 (51.85) |
| 7 days | Median [IQR] | 259.5 [201.5 - 352.75] | 229.5 [211.25 - 283.5] |
| 7 days | Missing / Non-Missing | 6 / 26 | 6 / 12 |
| 8 days | Mean (SD) | 304 (106.18) | 257.56 (67.03) |
| 8 days | Median [IQR] | 249 [230.25 - 375.75] | 235 [227 - 290] |
| 8 days | Missing / Non-Missing | 11 / 16 | 6 / 9 |
| 9 days | Mean (SD) | 328.36 (113.7) | 213.45 (53.15) |
| 9 days | Median [IQR] | 317.5 [235 - 402.75] | 207 [170 - 238] |
| 9 days | Missing / Non-Missing | 8 / 14 | 4 / 9 |
| 10 days | Mean (SD) | 295.92 (100.63) | 210.25 (51.95) |
| 10 days | Median [IQR] | 280 [216 - 374] | 200.5 [188.75 - 227] |
| 10 days | Missing / Non-Missing | 6 / 13 | 2 / 8 |
| 11 days | Mean (SD) | 298.7 (111.72) | 216.83 (88.64) |
| 11 days | Median [IQR] | 271 [243 - 405] | 181.5 [161 - 274.75] |
| 11 days | Missing / Non-Missing | 7 / 10 | 2 / 6 |
| 12 days | Mean (SD) | 271 (106.61) | 206.25 (69.5) |
| 12 days | Median [IQR] | 242 [194 - 351.25] | 194 [161.5 - 238.75] |
| 12 days | Missing / Non-Missing | 6 / 10 | 2 / 4 |
| 13 days | Mean (SD) | 268.63 (109.01) | 193 (5.66) |
| 13 days | Median [IQR] | 246 [201.75 - 348.25] | 193 [191 - 195] |
| 13 days | Missing / Non-Missing | 6 / 8 | 2 / 2 |
| 14 days | Mean (SD) | 229.11 (100.73) | 191.33 (61.45) |
| 14 days | Median [IQR] | 197 [158 - 237] | 176 [157.5 - 217.5] |
| 14 days | Missing / Non-Missing | 2 / 9 | 1 / 3 |

Lymphocytes (x10^9/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 1.33 (0.96) | 1.08 (0.46) |
| 0 days | Median [IQR] | 1.2 [0.95 - 1.5] | 1 [0.8 - 1.3] |
| 0 days | Missing / Non-Missing | 2 / 52 | 2 / 50 |
| 1 days | Mean (SD) | 1.28 (0.63) | 1.07 (0.45) |
| 1 days | Median [IQR] | 1.2 [0.9 - 1.65] | 1 [0.7 - 1.38] |
| 1 days | Missing / Non-Missing | 24 / 30 | 18 / 34 |
| 2 days | Mean (SD) | 1.45 (0.71) | 1.25 (0.49) |
| 2 days | Median [IQR] | 1.35 [1 - 1.8] | 1.1 [0.9 - 1.73] |
| 2 days | Missing / Non-Missing | 8 / 42 | 15 / 36 |
| 3 days | Mean (SD) | 1.3 (0.61) | 1.18 (0.53) |
| 3 days | Median [IQR] | 1.1 [1 - 1.6] | 1 [0.8 - 1.58] |
| 3 days | Missing / Non-Missing | 13 / 31 | 11 / 34 |
| 4 days | Mean (SD) | 1.33 (0.78) | 1.19 (0.57) |
| 4 days | Median [IQR] | 1.2 [0.7 - 1.6] | 1 [0.8 - 1.5] |
| 4 days | Missing / Non-Missing | 10 / 28 | 14 / 27 |
| 5 days | Mean (SD) | 1.3 (0.77) | 1.23 (0.56) |
| 5 days | Median [IQR] | 1.15 [0.9 - 1.5] | 1.1 [0.8 - 1.55] |
| 5 days | Missing / Non-Missing | 12 / 22 | 13 / 24 |
| 6 days | Mean (SD) | 1.35 (0.81) | 1.24 (0.54) |
| 6 days | Median [IQR] | 1.2 [0.83 - 1.58] | 1.15 [0.93 - 1.48] |
| 6 days | Missing / Non-Missing | 5 / 26 | 15 / 18 |
| 7 days | Mean (SD) | 1.28 (0.48) | 1.3 (0.54) |
| 7 days | Median [IQR] | 1.25 [0.95 - 1.6] | 1.3 [1 - 1.6] |
| 7 days | Missing / Non-Missing | 5 / 22 | 8 / 19 |
| 8 days | Mean (SD) | 1.4 (0.46) | 1.83 (1.92) |
| 8 days | Median [IQR] | 1.5 [1.05 - 1.65] | 1.4 [1.13 - 1.8] |
| 8 days | Missing / Non-Missing | 4 / 19 | 9 / 16 |
| 9 days | Mean (SD) | 1.37 (0.44) | 1.23 (0.61) |
| 9 days | Median [IQR] | 1.2 [1.1 - 1.6] | 1.2 [0.8 - 1.5] |
| 9 days | Missing / Non-Missing | 5 / 15 | 12 / 11 |
| 10 days | Mean (SD) | 1.75 (0.59) | 1.56 (0.68) |
| 10 days | Median [IQR] | 1.8 [1.2 - 2.03] | 1.65 [1.08 - 1.93] |
| 10 days | Missing / Non-Missing | 5 / 12 | 9 / 12 |
| 11 days | Mean (SD) | 1.82 (0.66) | 1.39 (0.83) |
| 11 days | Median [IQR] | 1.9 [1.45 - 2.08] | 1.6 [0.7 - 1.8] |
| 11 days | Missing / Non-Missing | 6 / 10 | 8 / 9 |
| 12 days | Mean (SD) | 1.97 (0.62) | 1.34 (0.98) |
| 12 days | Median [IQR] | 2 [1.5 - 2.5] | 0.9 [0.7 - 1.75] |
| 12 days | Missing / Non-Missing | 6 / 9 | 8 / 7 |
| 13 days | Mean (SD) | 1.83 (0.55) | 1.76 (0.85) |
| 13 days | Median [IQR] | 1.8 [1.55 - 2.05] | 1.9 [1.2 - 2.08] |
| 13 days | Missing / Non-Missing | 8 / 6 | 5 / 10 |
| 14 days | Mean (SD) | 1.79 (0.65) | 1.58 (0.92) |
| 14 days | Median [IQR] | 1.85 [1.25 - 2.23] | 1.55 [1.03 - 2] |
| 14 days | Missing / Non-Missing | 2 / 8 | 3 / 6 |

Lymphocytes (x10^9/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 1.18 (0.87) | 1.17 (0.59) |
| 0 days | Median [IQR] | 1.1 [0.9 - 1.3] | 1 [0.8 - 1.6] |
| 0 days | Missing / Non-Missing | 1 / 56 | 5 / 37 |
| 1 days | Mean (SD) | 1.18 (0.51) | 1.13 (0.44) |
| 1 days | Median [IQR] | 1.1 [0.8 - 1.48] | 1.2 [0.78 - 1.43] |
| 1 days | Missing / Non-Missing | 23 / 34 | 13 / 28 |
| 2 days | Mean (SD) | 1.3 (0.57) | 1.19 (0.48) |
| 2 days | Median [IQR] | 1.1 [1 - 1.5] | 1.1 [0.83 - 1.6] |
| 2 days | Missing / Non-Missing | 17 / 39 | 6 / 34 |
| 3 days | Mean (SD) | 1.34 (0.66) | 1.3 (0.6) |
| 3 days | Median [IQR] | 1.15 [1 - 1.6] | 1.3 [0.9 - 1.55] |
| 3 days | Missing / Non-Missing | 17 / 34 | 9 / 27 |
| 4 days | Mean (SD) | 1.36 (0.81) | 1.37 (0.64) |
| 4 days | Median [IQR] | 1.3 [0.85 - 1.7] | 1.4 [0.9 - 1.7] |
| 4 days | Missing / Non-Missing | 14 / 27 | 10 / 21 |
| 5 days | Mean (SD) | 1.48 (0.9) | 1.44 (0.66) |
| 5 days | Median [IQR] | 1.4 [0.95 - 1.7] | 1.35 [1.05 - 1.95] |
| 5 days | Missing / Non-Missing | 16 / 23 | 8 / 18 |
| 6 days | Mean (SD) | 1.55 (0.8) | 1.59 (0.81) |
| 6 days | Median [IQR] | 1.4 [1.18 - 1.83] | 1.35 [1.18 - 2.03] |
| 6 days | Missing / Non-Missing | 12 / 24 | 6 / 16 |
| 7 days | Mean (SD) | 1.51 (0.59) | 1.44 (0.7) |
| 7 days | Median [IQR] | 1.4 [1.23 - 1.98] | 1.3 [1.1 - 1.6] |
| 7 days | Missing / Non-Missing | 6 / 26 | 5 / 13 |
| 8 days | Mean (SD) | 1.58 (0.61) | 1.92 (1.03) |
| 8 days | Median [IQR] | 1.7 [1.1 - 2.1] | 1.7 [1.6 - 2] |
| 8 days | Missing / Non-Missing | 8 / 19 | 6 / 9 |
| 9 days | Mean (SD) | 1.69 (0.74) | 1.65 (0.84) |
| 9 days | Median [IQR] | 1.8 [1.05 - 2.23] | 1.55 [1.08 - 1.8] |
| 9 days | Missing / Non-Missing | 6 / 16 | 3 / 10 |
| 10 days | Mean (SD) | 1.8 (0.74) | 1.81 (0.84) |
| 10 days | Median [IQR] | 1.9 [1.33 - 2.25] | 1.7 [1.4 - 2.6] |
| 10 days | Missing / Non-Missing | 7 / 12 | 1 / 9 |
| 11 days | Mean (SD) | 1.75 (0.68) | 1.54 (0.71) |
| 11 days | Median [IQR] | 1.75 [1.53 - 1.98] | 1.6 [1.1 - 2] |
| 11 days | Missing / Non-Missing | 7 / 10 | 3 / 5 |
| 12 days | Mean (SD) | 2.25 (1.04) | 2 (1.33) |
| 12 days | Median [IQR] | 2.5 [1.4 - 2.9] | 1.95 [1.05 - 2.9] |
| 12 days | Missing / Non-Missing | 7 / 9 | 2 / 4 |
| 13 days | Mean (SD) | 2 (0.84) | 2.1 (1.56) |
| 13 days | Median [IQR] | 2.1 [1.65 - 2.55] | 2.1 [1.55 - 2.65] |
| 13 days | Missing / Non-Missing | 7 / 7 | 2 / 2 |
| 14 days | Mean (SD) | 1.72 (0.96) | 1.4 (0.76) |
| 14 days | Median [IQR] | 1.8 [1.1 - 2.3] | 1.3 [0.98 - 1.73] |
| 14 days | Missing / Non-Missing | 2 / 9 | 0 / 4 |

Neutrophils (x10^9/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 5.33 (3.45) | 4.87 (2.53) |
| 0 days | Median [IQR] | 4.8 [2.8 - 6.78] | 4.35 [3.23 - 5.58] |
| 0 days | Missing / Non-Missing | 2 / 52 | 2 / 50 |
| 1 days | Mean (SD) | 5.01 (4.48) | 4.89 (2.54) |
| 1 days | Median [IQR] | 3.9 [2.33 - 5.15] | 4.2 [3.3 - 5.95] |
| 1 days | Missing / Non-Missing | 24 / 30 | 18 / 34 |
| 2 days | Mean (SD) | 5.13 (3.44) | 5.1 (2.82) |
| 2 days | Median [IQR] | 4.2 [2.95 - 6.33] | 4.2 [3.18 - 6.65] |
| 2 days | Missing / Non-Missing | 8 / 42 | 15 / 36 |
| 3 days | Mean (SD) | 5.36 (2.86) | 5.05 (2.83) |
| 3 days | Median [IQR] | 5.3 [3.25 - 6.95] | 3.95 [3.15 - 6.4] |
| 3 days | Missing / Non-Missing | 13 / 31 | 11 / 34 |
| 4 days | Mean (SD) | 5.13 (2.7) | 5.48 (2.47) |
| 4 days | Median [IQR] | 4.6 [3.2 - 7.35] | 5 [3.85 - 6.35] |
| 4 days | Missing / Non-Missing | 11 / 27 | 14 / 27 |
| 5 days | Mean (SD) | 4.5 (1.94) | 5.53 (2.42) |
| 5 days | Median [IQR] | 4.15 [3.1 - 5.5] | 5 [4.1 - 6.3] |
| 5 days | Missing / Non-Missing | 12 / 22 | 14 / 23 |
| 6 days | Mean (SD) | 5.47 (3.18) | 5.52 (2.66) |
| 6 days | Median [IQR] | 4.7 [3.85 - 6.63] | 4.55 [3.65 - 7.78] |
| 6 days | Missing / Non-Missing | 5 / 26 | 15 / 18 |
| 7 days | Mean (SD) | 5.9 (3.24) | 6.06 (2.3) |
| 7 days | Median [IQR] | 5.25 [3.6 - 7.8] | 5.6 [4.3 - 7.95] |
| 7 days | Missing / Non-Missing | 5 / 22 | 8 / 19 |
| 8 days | Mean (SD) | 6.38 (3.17) | 6.2 (2.37) |
| 8 days | Median [IQR] | 6 [4.3 - 7.5] | 5.95 [4.33 - 7.83] |
| 8 days | Missing / Non-Missing | 4 / 19 | 9 / 16 |
| 9 days | Mean (SD) | 6.91 (3.88) | 6.41 (1.3) |
| 9 days | Median [IQR] | 6.5 [4.2 - 8.65] | 6.1 [5.3 - 7.35] |
| 9 days | Missing / Non-Missing | 5 / 15 | 12 / 11 |
| 10 days | Mean (SD) | 6.96 (3.87) | 6.59 (3.25) |
| 10 days | Median [IQR] | 6 [4.18 - 8.45] | 6.4 [4.68 - 7.78] |
| 10 days | Missing / Non-Missing | 5 / 12 | 9 / 12 |
| 11 days | Mean (SD) | 5.56 (2.29) | 7.23 (3.57) |
| 11 days | Median [IQR] | 4.7 [4.25 - 6.55] | 6.9 [6.1 - 8.2] |
| 11 days | Missing / Non-Missing | 5 / 11 | 8 / 9 |
| 12 days | Mean (SD) | 7.46 (4.26) | 9.24 (2.81) |
| 12 days | Median [IQR] | 6.1 [5.3 - 7.7] | 9.9 [7.2 - 11] |
| 12 days | Missing / Non-Missing | 6 / 9 | 8 / 7 |
| 13 days | Mean (SD) | 9.13 (5.63) | 7.77 (3.4) |
| 13 days | Median [IQR] | 6.95 [4.95 - 11.73] | 7.1 [5.3 - 10.8] |
| 13 days | Missing / Non-Missing | 8 / 6 | 6 / 9 |
| 14 days | Mean (SD) | 7.6 (3.11) | 7.18 (2.81) |
| 14 days | Median [IQR] | 6.7 [6 - 8.25] | 7.55 [5.9 - 8.53] |
| 14 days | Missing / Non-Missing | 2 / 8 | 3 / 6 |

Neutrophils (x10^9/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 5.6 (3.32) | 4.56 (2.28) |
| 0 days | Median [IQR] | 5 [3.25 - 7.25] | 4 [2.5 - 6.5] |
| 0 days | Missing / Non-Missing | 2 / 55 | 5 / 37 |
| 1 days | Mean (SD) | 5.63 (4.6) | 5.23 (3.08) |
| 1 days | Median [IQR] | 4 [2.85 - 7.35] | 4.3 [3.23 - 7] |
| 1 days | Missing / Non-Missing | 23 / 34 | 13 / 28 |
| 2 days | Mean (SD) | 5.19 (3.39) | 5.05 (3.25) |
| 2 days | Median [IQR] | 4.25 [2.9 - 6.18] | 4.7 [2.7 - 6.4] |
| 2 days | Missing / Non-Missing | 16 / 40 | 6 / 34 |
| 3 days | Mean (SD) | 4.94 (2.85) | 5.36 (3.95) |
| 3 days | Median [IQR] | 4.6 [3.03 - 6.6] | 3.9 [2.75 - 7.3] |
| 3 days | Missing / Non-Missing | 17 / 34 | 9 / 27 |
| 4 days | Mean (SD) | 5.45 (3.35) | 6.08 (5.52) |
| 4 days | Median [IQR] | 4.65 [3.58 - 5.85] | 4.4 [3.1 - 7.8] |
| 4 days | Missing / Non-Missing | 13 / 28 | 10 / 21 |
| 5 days | Mean (SD) | 5.98 (3.34) | 6.78 (4.44) |
| 5 days | Median [IQR] | 5.4 [3.8 - 6.15] | 5.65 [4 - 8.2] |
| 5 days | Missing / Non-Missing | 16 / 23 | 8 / 18 |
| 6 days | Mean (SD) | 5.86 (2.65) | 6.67 (4.42) |
| 6 days | Median [IQR] | 5.15 [4.08 - 6.93] | 6.1 [4.5 - 6.9] |
| 6 days | Missing / Non-Missing | 12 / 24 | 6 / 16 |
| 7 days | Mean (SD) | 6.29 (3.03) | 6.62 (4.01) |
| 7 days | Median [IQR] | 5.4 [4.13 - 7.98] | 5.5 [3.9 - 8.8] |
| 7 days | Missing / Non-Missing | 6 / 26 | 5 / 13 |
| 8 days | Mean (SD) | 6.79 (2.65) | 8.69 (5.16) |
| 8 days | Median [IQR] | 6.4 [5.35 - 8.1] | 6.3 [4.8 - 12.1] |
| 8 days | Missing / Non-Missing | 8 / 19 | 6 / 9 |
| 9 days | Mean (SD) | 7.2 (2.5) | 7.23 (4.92) |
| 9 days | Median [IQR] | 7.5 [4.55 - 9.38] | 5.6 [3.13 - 11.43] |
| 9 days | Missing / Non-Missing | 6 / 16 | 3 / 10 |
| 10 days | Mean (SD) | 6.56 (2.55) | 7.38 (4.35) |
| 10 days | Median [IQR] | 6.3 [4.35 - 8.2] | 5.6 [4.9 - 11.3] |
| 10 days | Missing / Non-Missing | 7 / 12 | 1 / 9 |
| 11 days | Mean (SD) | 6.91 (2.8) | 8.34 (2.83) |
| 11 days | Median [IQR] | 5.4 [4.85 - 8.65] | 9.8 [6.7 - 9.9] |
| 11 days | Missing / Non-Missing | 6 / 11 | 3 / 5 |
| 12 days | Mean (SD) | 6.46 (3.5) | 7.64 (2.83) |
| 12 days | Median [IQR] | 5.7 [3.6 - 7.1] | 7.4 [5.4 - 10.3] |
| 12 days | Missing / Non-Missing | 7 / 9 | 1 / 5 |
| 13 days | Mean (SD) | 8.12 (3.1) | 8.1 (4.38) |
| 13 days | Median [IQR] | 8 [5.7 - 10.05] | 8.1 [6.55 - 9.65] |
| 13 days | Missing / Non-Missing | 7 / 7 | 2 / 2 |
| 14 days | Mean (SD) | 5.5 (1.82) | 10.47 (4.84) |
| 14 days | Median [IQR] | 5.2 [4.6 - 6.5] | 12.2 [8.6 - 13.2] |
| 14 days | Missing / Non-Missing | 2 / 9 | 1 / 3 |













Procalcitonin (µg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 0.22 (0.21) | 0.51 (1.3) |
| 0 days | Median [IQR] | 0.13 [0.1 - 0.24] | 0.1 [0.1 - 0.2] |
| 0 days | Missing / Non-Missing | 15 / 39 | 19 / 33 |
| 1 days | Mean (SD) | 0.29 (0.29) | 2.73 (5.62) |
| 1 days | Median [IQR] | 0.17 [0.1 - 0.38] | 0.14 [0.1 - 1.96] |
| 1 days | Missing / Non-Missing | 38 / 16 | 36 / 16 |
| 2 days | Mean (SD) | 0.29 (0.32) | 2.24 (6.08) |
| 2 days | Median [IQR] | 0.18 [0.1 - 0.29] | 0.2 [0.1 - 0.88] |
| 2 days | Missing / Non-Missing | 20 / 30 | 27 / 24 |
| 3 days | Mean (SD) | 0.29 (0.28) | 0.96 (3.77) |
| 3 days | Median [IQR] | 0.2 [0.1 - 0.33] | 0.1 [0.1 - 0.14] |
| 3 days | Missing / Non-Missing | 24 / 20 | 23 / 22 |
| 4 days | Mean (SD) | 0.31 (0.29) | 1.74 (3.83) |
| 4 days | Median [IQR] | 0.2 [0.13 - 0.34] | 0.19 [0.1 - 0.58] |
| 4 days | Missing / Non-Missing | 27 / 11 | 23 / 18 |
| 5 days | Mean (SD) | 0.47 (0.52) | 1.38 (3.43) |
| 5 days | Median [IQR] | 0.27 [0.16 - 0.49] | 0.2 [0.11 - 0.37] |
| 5 days | Missing / Non-Missing | 24 / 10 | 21 / 16 |
| 6 days | Mean (SD) | 0.22 (0.28) | 1.24 (2.51) |
| 6 days | Median [IQR] | 0.1 [0.1 - 0.19] | 0.14 [0.11 - 0.65] |
| 6 days | Missing / Non-Missing | 14 / 17 | 18 / 15 |
| 7 days | Mean (SD) | 0.24 (0.21) | 0.32 (0.48) |
| 7 days | Median [IQR] | 0.1 [0.1 - 0.35] | 0.16 [0.11 - 0.26] |
| 7 days | Missing / Non-Missing | 13 / 14 | 12 / 15 |
| 8 days | Mean (SD) | 0.2 (0.2) | 0.51 (0.9) |
| 8 days | Median [IQR] | 0.1 [0.1 - 0.17] | 0.22 [0.1 - 0.43] |
| 8 days | Missing / Non-Missing | 11 / 12 | 13 / 12 |
| 9 days | Mean (SD) | 0.17 (0.19) | 0.68 (0.77) |
| 9 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.3 [0.15 - 0.81] |
| 9 days | Missing / Non-Missing | 8 / 12 | 14 / 9 |
| 10 days | Mean (SD) | 0.23 (0.22) | 0.38 (0.49) |
| 10 days | Median [IQR] | 0.1 [0.1 - 0.33] | 0.2 [0.1 - 0.4] |
| 10 days | Missing / Non-Missing | 11 / 6 | 12 / 9 |
| 11 days | Mean (SD) | 0.22 (0.21) | 1.75 (2.9) |
| 11 days | Median [IQR] | 0.1 [0.1 - 0.33] | 0.4 [0.25 - 1.9] |
| 11 days | Missing / Non-Missing | 7 / 9 | 13 / 4 |
| 12 days | Mean (SD) | 0.11 (0.08) | 0.56 (0.61) |
| 12 days | Median [IQR] | 0.1 [0.09 - 0.1] | 0.27 [0.2 - 0.63] |
| 12 days | Missing / Non-Missing | 7 / 8 | 10 / 5 |
| 13 days | Mean (SD) | 0.38 (0.46) | 0.48 (0.85) |
| 13 days | Median [IQR] | 0.23 [0.12 - 0.33] | 0.1 [0.1 - 0.29] |
| 13 days | Missing / Non-Missing | 8 / 6 | 8 / 7 |
| 14 days | Mean (SD) | 0.22 (0.19) | 0.89 (1.04) |
| 14 days | Median [IQR] | 0.15 [0.1 - 0.27] | 0.5 [0.26 - 1.13] |
| 14 days | Missing / Non-Missing | 6 / 4 | 5 / 4 |

Procalcitonin (µg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 0.48 (1.64) | 0.19 (0.16) |
| 0 days | Median [IQR] | 0.16 [0.1 - 0.29] | 0.12 [0.1 - 0.2] |
| 0 days | Missing / Non-Missing | 13 / 44 | 16 / 26 |
| 1 days | Mean (SD) | 0.3 (0.29) | 0.28 (0.46) |
| 1 days | Median [IQR] | 0.18 [0.1 - 0.4] | 0.12 [0.1 - 0.21] |
| 1 days | Missing / Non-Missing | 36 / 21 | 28 / 13 |
| 2 days | Mean (SD) | 0.46 (0.87) | 0.24 (0.31) |
| 2 days | Median [IQR] | 0.2 [0.1 - 0.4] | 0.1 [0.1 - 0.25] |
| 2 days | Missing / Non-Missing | 25 / 31 | 20 / 20 |
| 3 days | Mean (SD) | 0.27 (0.26) | 0.33 (0.48) |
| 3 days | Median [IQR] | 0.2 [0.1 - 0.29] | 0.16 [0.1 - 0.2] |
| 3 days | Missing / Non-Missing | 24 / 27 | 21 / 15 |
| 4 days | Mean (SD) | 0.37 (0.39) | 0.22 (0.25) |
| 4 days | Median [IQR] | 0.2 [0.13 - 0.34] | 0.1 [0.1 - 0.21] |
| 4 days | Missing / Non-Missing | 26 / 15 | 21 / 10 |
| 5 days | Mean (SD) | 0.3 (0.29) | 0.23 (0.22) |
| 5 days | Median [IQR] | 0.2 [0.12 - 0.3] | 0.1 [0.1 - 0.34] |
| 5 days | Missing / Non-Missing | 27 / 12 | 16 / 10 |
| 6 days | Mean (SD) | 0.19 (0.18) | 0.17 (0.08) |
| 6 days | Median [IQR] | 0.11 [0.1 - 0.2] | 0.14 [0.1 - 0.24] |
| 6 days | Missing / Non-Missing | 22 / 14 | 15 / 7 |
| 7 days | Mean (SD) | 0.23 (0.2) | 0.13 (0.05) |
| 7 days | Median [IQR] | 0.1 [0.1 - 0.3] | 0.1 [0.1 - 0.16] |
| 7 days | Missing / Non-Missing | 12 / 20 | 12 / 6 |
| 8 days | Mean (SD) | 0.27 (0.31) | 0.11 (0.04) |
| 8 days | Median [IQR] | 0.11 [0.1 - 0.26] | 0.1 [0.1 - 0.11] |
| 8 days | Missing / Non-Missing | 14 / 13 | 10 / 5 |
| 9 days | Mean (SD) | 0.3 (0.35) | 0.18 (0.18) |
| 9 days | Median [IQR] | 0.1 [0.1 - 0.34] | 0.1 [0.1 - 0.16] |
| 9 days | Missing / Non-Missing | 12 / 10 | 8 / 5 |
| 10 days | Mean (SD) | 0.22 (0.19) | 0.1 (0.02) |
| 10 days | Median [IQR] | 0.1 [0.1 - 0.28] | 0.1 [0.09 - 0.11] |
| 10 days | Missing / Non-Missing | 12 / 7 | 6 / 4 |
| 11 days | Mean (SD) | 0.32 (0.4) | 0.1 (0.02) |
| 11 days | Median [IQR] | 0.15 [0.1 - 0.41] | 0.1 [0.09 - 0.11] |
| 11 days | Missing / Non-Missing | 6 / 11 | 5 / 3 |
| 12 days | Mean (SD) | 0.29 (0.5) | 0.1 (0.01) |
| 12 days | Median [IQR] | 0.1 [0.06 - 0.12] | 0.1 [0.1 - 0.1] |
| 12 days | Missing / Non-Missing | 10 / 6 | 3 / 3 |
| 13 days | Mean (SD) | 0.26 (0.28) | 0.12 (0.06) |
| 13 days | Median [IQR] | 0.12 [0.1 - 0.26] | 0.12 [0.1 - 0.14] |
| 13 days | Missing / Non-Missing | 8 / 6 | 2 / 2 |
| 14 days | Mean (SD) | 0.21 (0.17) | 0.17 (0.15) |
| 14 days | Median [IQR] | 0.11 [0.1 - 0.28] | 0.17 [0.11 - 0.22] |
| 14 days | Missing / Non-Missing | 4 / 7 | 2 / 2 |

### Plots



### Efficacy estimates

CRP (mg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -12.614 | -18.451 | -6.776 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -7.758 | -11.910 | -3.605 | 0.000 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 4.856 | -1.734 | 11.446 | 0.149 |
| Day 14 level by treatment | Standard of care (SOC) | 37.793 | 21.084 | 54.503 | 0.000 |
| Day 14 level by treatment | Hydroxychloroquine + SOC | 42.974 | 24.536 | 61.411 | 0.000 |
| Day 14 treatment difference | Hydroxychloroquine + SOC | 5.180 | -18.101 | 28.462 | 0.663 |

CRP (mg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -15.675 | -20.902 | -10.448 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | -9.649 | -13.547 | -5.751 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | 6.026 | -0.045 | 12.097 | 0.052 |
| Day 14 level by treatment | Standard of care (SOC) | 26.701 | 16.935 | 36.466 | 0.000 |
| Day 14 level by treatment | Remdesivir + SOC | 10.602 | 5.595 | 15.610 | 0.000 |
| Day 14 treatment difference | Remdesivir + SOC | -16.098 | -26.775 | -5.422 | 0.003 |

Ferritin (µg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 10.131 | -7.145 | 27.406 | 0.250 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 7.282 | -10.721 | 25.284 | 0.428 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | -2.849 | -27.793 | 22.094 | 0.823 |
| Day 14 level by treatment | Standard of care (SOC) | 616.126 | 415.900 | 816.352 | 0.000 |
| Day 14 level by treatment | Hydroxychloroquine + SOC | 610.460 | 410.031 | 810.888 | 0.000 |
| Day 14 treatment difference | Hydroxychloroquine + SOC | -5.666 | -268.573 | 257.240 | 0.966 |

Ferritin (µg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -24.011 | -42.544 | -5.477 | 0.011 |
| Slope 1st week by treatment | Remdesivir + SOC | -0.533 | -28.428 | 27.362 | 0.970 |
| Difference in 1st week slope | Remdesivir + SOC | 23.477 | -9.946 | 56.901 | 0.169 |
| Day 14 level by treatment | Standard of care (SOC) | 597.689 | 419.167 | 776.210 | 0.000 |
| Day 14 level by treatment | Remdesivir + SOC | 695.204 | 430.890 | 959.517 | 0.000 |
| Day 14 treatment difference | Remdesivir + SOC | 97.515 | -205.387 | 400.417 | 0.528 |

LDH (U/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -5.305 | -8.742 | -1.868 | 0.002 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -3.371 | -7.234 | 0.492 | 0.087 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 1.934 | -3.205 | 7.073 | 0.461 |
| Day 14 level by treatment | Standard of care (SOC) | 198.091 | 169.616 | 226.566 | 0.000 |
| Day 14 level by treatment | Hydroxychloroquine + SOC | 200.403 | 170.171 | 230.636 | 0.000 |
| Day 14 treatment difference | Hydroxychloroquine + SOC | 2.312 | -39.106 | 43.731 | 0.913 |

LDH (U/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -7.635 | -10.575 | -4.696 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | -3.185 | -6.948 | 0.579 | 0.097 |
| Difference in 1st week slope | Remdesivir + SOC | 4.450 | -0.318 | 9.219 | 0.067 |
| Day 14 level by treatment | Standard of care (SOC) | 198.348 | 174.417 | 222.278 | 0.000 |
| Day 14 level by treatment | Remdesivir + SOC | 191.667 | 159.838 | 223.497 | 0.000 |
| Day 14 treatment difference | Remdesivir + SOC | -6.680 | -46.348 | 32.987 | 0.741 |

Lymphocytes (x10^9/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.056 | 0.028 | 0.083 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 0.062 | 0.037 | 0.087 | 0.000 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 0.006 | -0.030 | 0.043 | 0.736 |
| Day 14 level by treatment | Standard of care (SOC) | 2.454 | 2.010 | 2.899 | 0.000 |
| Day 14 level by treatment | Hydroxychloroquine + SOC | 1.787 | 1.455 | 2.118 | 0.000 |
| Day 14 treatment difference | Hydroxychloroquine + SOC | -0.668 | -1.216 | -0.120 | 0.017 |

Lymphocytes (x10^9/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.084 | 0.061 | 0.108 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | 0.096 | 0.066 | 0.127 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | 0.012 | -0.026 | 0.050 | 0.541 |
| Day 14 level by treatment | Standard of care (SOC) | 2.366 | 1.972 | 2.761 | 0.000 |
| Day 14 level by treatment | Remdesivir + SOC | 2.210 | 1.710 | 2.710 | 0.000 |
| Day 14 treatment difference | Remdesivir + SOC | -0.157 | -0.786 | 0.473 | 0.626 |

Neutrophils (x10^9/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.043 | -0.050 | 0.136 | 0.364 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 0.049 | -0.045 | 0.144 | 0.309 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 0.006 | -0.126 | 0.139 | 0.928 |
| Day 14 level by treatment | Standard of care (SOC) | 6.541 | 5.244 | 7.838 | 0.000 |
| Day 14 level by treatment | Hydroxychloroquine + SOC | 6.780 | 5.405 | 8.155 | 0.000 |
| Day 14 treatment difference | Hydroxychloroquine + SOC | 0.239 | -1.639 | 2.117 | 0.803 |

Neutrophils (x10^9/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.021 | -0.069 | 0.111 | 0.649 |
| Slope 1st week by treatment | Remdesivir + SOC | 0.045 | -0.060 | 0.150 | 0.400 |
| Difference in 1st week slope | Remdesivir + SOC | 0.024 | -0.114 | 0.162 | 0.732 |
| Day 14 level by treatment | Standard of care (SOC) | 6.180 | 4.932 | 7.428 | 0.000 |
| Day 14 level by treatment | Remdesivir + SOC | 4.937 | 3.603 | 6.270 | 0.000 |
| Day 14 treatment difference | Remdesivir + SOC | -1.244 | -3.058 | 0.571 | 0.179 |

Procalcitonin (µg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.021 | -0.037 | -0.005 | 0.011 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -0.056 | -0.087 | -0.025 | 0.000 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | -0.035 | -0.069 | -0.002 | 0.038 |
| Day 14 level by treatment | Standard of care (SOC) | 0.202 | 0.099 | 0.304 | 0.000 |
| Day 14 level by treatment | Hydroxychloroquine + SOC | 0.217 | 0.098 | 0.337 | 0.000 |
| Day 14 treatment difference | Hydroxychloroquine + SOC | 0.016 | -0.137 | 0.168 | 0.842 |

Procalcitonin (µg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.019 | -0.028 | -0.010 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | -0.016 | -0.027 | -0.006 | 0.002 |
| Difference in 1st week slope | Remdesivir + SOC | 0.003 | -0.011 | 0.016 | 0.683 |
| Day 14 level by treatment | Standard of care (SOC) | 0.136 | 0.089 | 0.183 | 0.000 |
| Day 14 level by treatment | Remdesivir + SOC | 0.141 | 0.069 | 0.214 | 0.000 |
| Day 14 treatment difference | Remdesivir + SOC | 0.006 | -0.080 | 0.091 | 0.898 |

## SARS-CoV2 antibodies at day 90

### Descriptives

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| Receptor-bindind domain | Mean (SD) | 60.8 (41.7) | 45.4 (36.4) |
|  | Median (IQR) | 58.6 (26.4 - 96.1) | 40.4 (11.3 - 63.3) |
| Normalised receptor-binding domain | Mean (SD) | 17.4 (12.1) | 15.5 (9) |
|  | Median (IQR) | 15.5 (9 - 23.2) | 15 (8.4 - 22.1) |
| log10 ACE2 receptor-binding domain | Mean (SD) | 1.26 (0.71) | 1.17 (0.69) |
|  | Median (IQR) | 1.22 (0.73 - 1.93) | 1.21 (0.6 - 1.73) |

Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| Receptor-bindind domain | Mean (SD) | 51 (43.4) | 79.2 (43.4) |
|  | Median (IQR) | 40.7 (13.2 - 90.9) | 69 (51.6 - 102) |
| Normalised receptor-binding domain | Mean (SD) | 15.6 (11.2) | 21.7 (11.8) |
|  | Median (IQR) | 15.2 (5.7 - 25.1) | 17.7 (13.3 - 30.9) |
| log10 ACE2 receptor-binding domain | Mean (SD) | 1.11 (0.72) | 1.3 (0.54) |
|  | Median (IQR) | 1.09 (0.46 - 1.63) | 1.33 (1.15 - 1.46) |

### Marginal probability estimates by treatment group and difference

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC | Estimated marginal treatment effect |
| Receptor-bindind domain | 60.8 (49.3 to 72.3) | 45.4 (33.2 to 57.6) | -15.4 (-32.1 to 1.4) |
| Normalised receptor-binding domain | 17.4 (14.3 to 20.6) | 15.5 (12.2 to 18.9) | -1.9 (-6.5 to 2.7) |
| log10 ACE2 receptor-binding domain | 1.26 (1.06 to 1.47) | 1.17 (0.95 to 1.39) | -0.09 (-0.39 to 0.21) |

Estimates are presented with 95% confidence limits



Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC | Estimated marginal treatment effect |
| Receptor-bindind domain | 51 (38.8 to 63.2) | 79.2 (64.4 to 94) | 28.2 (9 to 47.4) |
| Normalised receptor-binding domain | 15.6 (12.4 to 18.8) | 21.7 (17.8 to 25.6) | 6.1 (1 to 11.1) |
| log10 ACE2 receptor-binding domain | 1.11 (0.93 to 1.29) | 1.3 (1.07 to 1.52) | 0.19 (-0.1 to 0.47) |



Estimates are presented with 95% confidence limits

## Time to last discharge

### HCQ



### Remdesivir



# Adverse Events

## AE Summary

Summary of Adverse Events

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Number of AEs | [45] 28 (32.2%) | [32] 19 (36.5%) | [16] 11 (26.2%) |
| Number of patients with any AEs? | 28 (32.2%) | 19 (36.5%) | 11 (26.2%) |
| Number of patients with one AE | 20 (23%) | 12 (23.1%) | 8 (19%) |
| Number of patients with two AE | 2 (2.3%) | 3 (5.8%) | 1 (2.4%) |
| Number of patients with three or more AEs | 6 (6.9%) | 4 (7.7%) | 2 (4.8%) |
| Number of SAEs | [24] 16 (18.4%) | [15] 9 (17.3%) | [6] 6 (14.3%) |
| Number of patients with any SAEs? | 16 (18.4%) | 9 (17.3%) | 6 (14.3%) |

The numbers are [Number of events] Number of patients (percentage of patients), or Number of patients (percentage of patients)

## By System Organ Class and Preferred Term

Adverse Events by System Organ Class and Preferred term

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| System Organ Class | Preferred Term | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Blood and lymphatic system disorders | #Total | [2] 1 (1.1%) |  |  |
|  | Leukopenia | [1] 1 (1.1%) |  |  |
|  | Thrombocytopenia | [1] 1 (1.1%) |  |  |
| Cardiac disorders | #Total |  | [1] 1 (1.9%) | [3] 2 (4.8%) |
|  | Arrhythmia |  |  | [2] 1 (2.4%) |
|  | Ventricular tachycardia |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
| Gastrointestinal disorders | #Total | [5] 5 (5.7%) | [1] 1 (1.9%) | [4] 3 (7.1%) |
|  | Abdominal pain | [1] 1 (1.1%) |  |  |
|  | Diarrhoea | [1] 1 (1.1%) |  |  |
|  | Diarrhoea haemorrhagic | [1] 1 (1.1%) |  |  |
|  | Gastrooesophageal reflux disease |  |  | [1] 1 (2.4%) |
|  | Intestinal pseudo-obstruction |  | [1] 1 (1.9%) |  |
|  | Nausea |  |  | [2] 2 (4.8%) |
|  | Pancreatic failure | [1] 1 (1.1%) |  |  |
|  | Vomiting | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| General disorders and administration site conditions | #Total | [2] 2 (2.3%) | [1] 1 (1.9%) | [2] 2 (4.8%) |
|  | Chest pain |  |  | [1] 1 (2.4%) |
|  | General physical health deterioration |  |  | [1] 1 (2.4%) |
|  | Medical device site reaction | [1] 1 (1.1%) |  |  |
|  | Pyrexia | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Hepatobiliary disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Cholecystitis | [1] 1 (1.1%) |  |  |
| Infections and infestations | #Total | [3] 3 (3.4%) | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | COVID-19 | [1] 1 (1.1%) |  |  |
|  | Infection |  |  | [1] 1 (2.4%) |
|  | Pneumonia bacterial | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Superinfection bacterial | [1] 1 (1.1%) |  |  |
| Injury, poisoning and procedural complications | #Total | [2] 2 (2.3%) |  |  |
|  | Hepatobiliary procedural complication | [1] 1 (1.1%) |  |  |
|  | Procedural pneumothorax | [1] 1 (1.1%) |  |  |
| Investigations | #Total | [11] 6 (6.9%) | [5] 4 (7.7%) | [3] 3 (7.1%) |
|  | Alanine aminotransferase increased | [2] 1 (1.1%) | [2] 2 (3.8%) |  |
|  | Amylase increased | [1] 1 (1.1%) |  |  |
|  | Aspartate aminotransferase increased | [4] 4 (4.6%) | [1] 1 (1.9%) |  |
|  | Blood creatine phosphokinase increased | [1] 1 (1.1%) |  |  |
|  | Electrocardiogram QT prolonged | [2] 2 (2.3%) |  |  |
|  | Fibrin D dimer increased |  |  | [1] 1 (2.4%) |
|  | Gamma-glutamyltransferase increased | [1] 1 (1.1%) |  |  |
|  | Hepatic enzyme increased |  |  | [2] 2 (4.8%) |
|  | Myocardial necrosis marker increased |  | [1] 1 (1.9%) |  |
|  | Neutrophil count decreased |  | [1] 1 (1.9%) |  |
| Metabolism and nutrition disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Hypercalcaemia | [1] 1 (1.1%) |  |  |
| Musculoskeletal and connective tissue disorders | #Total |  | [3] 1 (1.9%) | [1] 1 (2.4%) |
|  | Arthralgia |  | [1] 1 (1.9%) |  |
|  | Arthritis reactive |  | [1] 1 (1.9%) |  |
|  | Joint swelling |  | [1] 1 (1.9%) |  |
|  | Tendonitis |  |  | [1] 1 (2.4%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | #Total | [1] 1 (1.1%) |  |  |
|  | Neoplasm malignant | [1] 1 (1.1%) |  |  |
| Nervous system disorders | #Total | [3] 3 (3.4%) | [2] 2 (3.8%) |  |
|  | Haemorrhage intracranial | [1] 1 (1.1%) |  |  |
|  | Headache |  | [1] 1 (1.9%) |  |
|  | Loss of consciousness | [1] 1 (1.1%) |  |  |
|  | Syncope | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Renal and urinary disorders | #Total |  | [2] 2 (3.8%) |  |
|  | Renal failure |  | [2] 2 (3.8%) |  |
| Respiratory, thoracic and mediastinal disorders | #Total | [12] 11 (12.6%) | [13] 8 (15.4%) | [2] 2 (4.8%) |
|  | Bronchopleural fistula | [1] 1 (1.1%) |  |  |
|  | Chronic obstructive pulmonary disease |  | [2] 1 (1.9%) |  |
|  | Cough | [1] 1 (1.1%) |  |  |
|  | Dyspnoea |  | [4] 2 (3.8%) |  |
|  | Pulmonary embolism | [1] 1 (1.1%) |  |  |
|  | Respiratory distress | [2] 2 (2.3%) | [5] 4 (7.7%) | [1] 1 (2.4%) |
|  | Respiratory failure | [7] 7 (8%) | [2] 1 (1.9%) | [1] 1 (2.4%) |
| Skin and subcutaneous tissue disorders | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Alopecia | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Vascular disorders | #Total | [1] 1 (1.1%) | [2] 2 (3.8%) |  |
|  | Hypotension |  | [1] 1 (1.9%) |  |
|  | Thrombophlebitis |  | [1] 1 (1.9%) |  |
|  | Thrombosis | [1] 1 (1.1%) |  |  |

## Serious Adverse Events

Serious Adverse Events by System Organ Class and Preferred term

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| System Organ Class | Preferred Term | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Gastrointestinal disorders | #Total | [2] 2 (2.3%) |  |  |
|  | Abdominal pain | [1] 1 (1.1%) |  |  |
|  | Diarrhoea haemorrhagic | [1] 1 (1.1%) |  |  |
| General disorders and administration site conditions | #Total | [1] 1 (1.1%) |  | [2] 2 (4.8%) |
|  | Chest pain |  |  | [1] 1 (2.4%) |
|  | General physical health deterioration |  |  | [1] 1 (2.4%) |
|  | Pyrexia | [1] 1 (1.1%) |  |  |
| Hepatobiliary disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Cholecystitis | [1] 1 (1.1%) |  |  |
| Infections and infestations | #Total | [3] 3 (3.4%) |  |  |
|  | COVID-19 | [1] 1 (1.1%) |  |  |
|  | Pneumonia bacterial | [1] 1 (1.1%) |  |  |
|  | Superinfection bacterial | [1] 1 (1.1%) |  |  |
| Injury, poisoning and procedural complications | #Total | [2] 2 (2.3%) |  |  |
|  | Hepatobiliary procedural complication | [1] 1 (1.1%) |  |  |
|  | Procedural pneumothorax | [1] 1 (1.1%) |  |  |
| Investigations | #Total | [3] 3 (3.4%) |  | [2] 2 (4.8%) |
|  | Alanine aminotransferase increased | [1] 1 (1.1%) |  |  |
|  | Aspartate aminotransferase increased | [1] 1 (1.1%) |  |  |
|  | Blood creatine phosphokinase increased | [1] 1 (1.1%) |  |  |
|  | Hepatic enzyme increased |  |  | [2] 2 (4.8%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | #Total | [1] 1 (1.1%) |  |  |
|  | Neoplasm malignant | [1] 1 (1.1%) |  |  |
| Nervous system disorders | #Total | [2] 2 (2.3%) |  |  |
|  | Haemorrhage intracranial | [1] 1 (1.1%) |  |  |
|  | Loss of consciousness | [1] 1 (1.1%) |  |  |
| Renal and urinary disorders | #Total |  | [2] 2 (3.8%) |  |
|  | Renal failure |  | [2] 2 (3.8%) |  |
| Respiratory, thoracic and mediastinal disorders | #Total | [9] 8 (9.2%) | [13] 8 (15.4%) | [2] 2 (4.8%) |
|  | Bronchopleural fistula | [1] 1 (1.1%) |  |  |
|  | Chronic obstructive pulmonary disease |  | [2] 1 (1.9%) |  |
|  | Dyspnoea |  | [4] 2 (3.8%) |  |
|  | Pulmonary embolism | [1] 1 (1.1%) |  |  |
|  | Respiratory distress | [1] 1 (1.1%) | [5] 4 (7.7%) | [1] 1 (2.4%) |
|  | Respiratory failure | [6] 6 (6.9%) | [2] 1 (1.9%) | [1] 1 (2.4%) |

## Suspected Unexpected Serious Adverse Reaction

Suspected Unexpected Serious Adverse Reaction by System Organ Class and Preferred term

|  |  |  |
| --- | --- | --- |
| System Organ Class | Preferred Term | Standard of care (SOC) |
| Gastrointestinal disorders | #Total | [1] 1 (1.1%) |
|  | Diarrhoea haemorrhagic | [1] 1 (1.1%) |

END